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ABSTRACT 
Kate Elizabeth Coleman: Coordination of Replication-Coupled Protein Destruction and Origin 
Licensing Control During Cell Cycle Transitions. 
(Under the direction of Jeanette Gowen Cook) 
 
 Timely ubiquitin-mediated protein degradation is fundamental to cell cycle control, but 
the precise degradation order at each cell cycle phase transition is still unclear. In this work, we 
investigated the degradation order of targets of a single human E3 ubiquitin ligase important for 
S-phase proteolysis, known as CRL4Cdt2.  We showed that in both synchronized cells and 
asynchronously proliferating cells, CRL4Cdt2-mediated degradation of the cell cycle proteins 
Cdt1, p21, and PR-Set7 occurs in a consistent order during both the G1/S transition and during 
DNA repair synthesis.  We additionally showed that these different rates of degradation are 
determined by the CRL4Cdt2 targeting motif called a PCNA interacting peptide (PIP) degron, 
which allows for substrate binding to DNA-bound proliferating cell nuclear antigen (PCNA) and 
recognition by CRL4Cdt2.  Manipulating the degradation order such that p21 was degraded 
prematurely promoted stalled replication in mid-S phase and sensitivity to replication arrest.  
Collectively, these results establish for the first time that ordered degradation at the G1/S 
transition, facilitated by the CRL4Cdt2 E3 ligase, is important to avoid replication stress and 
genome instability. 
 Another process that is tightly controlled at cell cycle transitions is replication origin 
licensing, in which replication initiation sites, or origins, are rendered competent for replication 
by the DNA loading of the replicative helicase, the Mini-Chromosome Maintenance (MCM) 
complex.  Through the collective action of ORC, Cdc6, and Cdt1 proteins, MCM complexes are 
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loaded onto DNA exclusively in G1 phase in an inactive form, and become activated by protein 
kinases during S phase.  MCM loading is strictly inhibited beyond the G1/S transition and during 
cellular quiescence (G0 phase), although at the time of this study, mechanisms contributing to 
this licensing block specifically during G0 phase were poorly understood.  To identify novel 
protein mediators of quiescence establishment and maintenance, we performed a mass 
spectrometry screen designed to identify differential MCM binding partners in quiescent vs. 
proliferating cells.  We prioritized several novel MCM interactions uncovered from this initial 
screen for further validation experiments, including three with previously characterized roles in 
the control of cell proliferation/quiescence:  Sam68 (KHDRBS1), Nme1, and Host Cell Factor C1 
(HCFC1).  Future work will be needed to improve the initial screening approach and to establish 
a role for these new MCM interactions in cell cycle control and/or MCM loading regulation.
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Chapter 1:  Introduction 
An overview of the eukaryotic cell cycle 
 The eukaryotic cell cycle is a highly regulated process that directs accurate cell 
growth, duplication, and division to produce two identical daughter cells.  Events during the 
cell cycle are described in terms of four distinct phases (Figure 1.1).  During G1 (Gap 1) 
phase, the cell senses extracellular cues and if conditions are appropriate for cell division, 
expresses components necessary for deoxyribonucleic acid (DNA) replication.  If conditions 
are unfavorable for division, the cell can also at this point exit to become quiescent; during 
quiescence (also G0 phase) cells are still metabolically active, but express low levels of cell 
cycle promoting factors and do not proliferate.  When cells have committed to undergo cell 
division (termed the “restriction point” in late G1; (Pardee 1974) they progress into S phase, 
when they duplicate the entire genome.  Completion of DNA duplication in S phase gives 
rise to a second gap phase, G2, in which the cell makes preparations for mitosis.  Finally, 
during mitosis, the newly replicated chromosomes are segregated to separate nuclei and 
subsequent cell division produces two new daughter cells.  Mitosis is divided into four 
distinct stages: prophase, metaphase, anaphase, and telophase (reviewed in (Schafer 
1998). 
 Transitions between cell cycle phases are controlled in large part by the activity of 
cyclin-dependent kinases (CDKs), which are a family of enzymes that phosphorylate various 
protein substrates involved in cell cycle progression.  As their name suggests, CDKs require 
the presence of proteins called cyclins; cyclins have no enzymatic activity on their own but 
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activate CDKs upon binding to them.  Cyclin levels oscillate during the cell cycle, owing to 
changes in synthesis (controlled by transcription and translation) as well as their destruction 
via ubiquitin-mediated proteolysis, which will be discussed in the next section.  These 
oscillations allow different cyclin-CDK complexes to form at different times to trigger events 
specific to a given cell cycle phase (reviewed in (Morgan 1997; Schafer 1998).  Cyclin 
activity is also negatively regulated by cyclin-dependent kinase inhibitors (CKIs).  There are 
two main families of CKIs; the INK4 family, which includes p16INK4, and the CIP family 
typified by p21CIP1/WAF1, p27Kip1, and p57Kip2.  The abundance of these proteins is tightly 
controlled during cell cycle progression (reviewed in (Sherr and Roberts 1999; Sheaff 1996).  
A list of cyclin-CDK complexes and CKIs in mammalian cells is detailed in Figure 1.1. 
 The precise order with which events occur in each of these cell cycle phases is 
crucial, and many types of human cancers arise as a consequence of inappropriate cell 
cycle transitions.  While the ordering of cell cycle events have been studied extensively in 
terms of this four-stage model, the cell cycle likely also consists of “subphases” at key 
transitions to ensure orderly progression from one phase to the next.  The sequence of 
events occurring at these critical transition phases, however, has not been as well studied 
and is the focus of this dissertation.  Chapter 2 will look at the ordered degradation of 
proteins at the G1/S transition and its importance to S phase progression.  Chapter 3 will 
examine how replication inhibition is established as cells transition from the active cell cycle 
to cellular quiescence.      
The ubiquitin-proteasome pathway drives cell cycle transitions  
As mentioned above, by causing the orderly destruction of cyclins and other 
important cell cycle regulators, the ubiquitin-proteasome pathway is also central to 
coordinating cell cycle transitions.  In the process, a small 76-amino-acid peptide called  
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Figure 1.1. 
 
 
Figure 1.1.  An overview of eukaryotic cell cycle regulation.  Events occurring during 
different phases of the eukaryotic cell cycle are highlighted.  This dissertation emphasizes 
the ordering of events specifically at transitions between phases, marked by red arrows.  
Cell cycle transitions are positively regulated by cyclin-CDKs specific to each phase (left 
table) and negatively regulated by interactions of CDKs with CKIs (right table). 
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ubiquitin is attached to proteins via an isopeptide bond between the C-terminal glycine of 
ubiquitin and one or more lysines in the substrate.  Successive ubiquitylations form 
polyubiquitin chains that in most cases target proteins for destruction.  In some instances, 
however, addition of ubiquitin affects the function, enzymatic activity, or subcellular 
localization of a protein substrate without affecting its stability (reviewed in (Komander and 
Rape 2012). The ubiquitin-proteasome system consists of three main enzymatic activities.  
Ubiquitin is first activated by an E1 activating enzyme in a process that consumes 
adenosine triphosphate (ATP).  The ubiquitin is then transferred from the E1 to an E2 
conjugating enzyme.  Finally, the E2 interacts with an E3 ubiqutin ligase which also binds to 
the substrate, commonly (although not universally) via a short destruction motif called a 
“degron” sequence (discussed in the next section).  This interaction ultimately promotes 
ubiquitin transfer to the substrate and targeting to the 26S proteasome for protein 
destruction (Figure 1.2A). (reviewed in (Nakayama and Nakayama 2006; Petroski and 
Deshaies 2005; Komander and Rape 2012) 
E3 ubiquitin ligases involved in substrate recognition can be classified into two main 
groups based on their method of ubiquitin conjugation and targeting motifs:  HECT 
(Homologous to E6-AP C-terminus) or RING (Really Interesting New Gene) (Deshaies and 
Joazeiro 2009).  The best understood E3s with roles in cell cycle control are the cullin-RING-
ligases (CRLs) as well as their relative, the anaphase-promoting complex/cyclosome 
(APC/C), and these will be the main focus of this dissertation work.  Cullin 1 (SCF)- and 
Cullin 4 (CRL4)-based E3 ligase complexes adopt a similar architecture, shown in Figure 
1.2B. The scaffold proteins Cul1 and Cul4 (cullin 4A or cullin 4B) complex with small RING 
finger proteins (Rbx/Roc) to form the catalytic core of CRL1 (SCF) and CRL4 complexes, 
respectively.  Rbx 1/2 proteins are needed to recruit E2 conjugating enzymes.  Cullins also 
bind adaptor proteins (Skp1 for CRL1 and DDB1 for CRL4) that function to bridge cullins  
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Figure 1.2. 
 
 
 
Figure 1.2.  The ubiquitin proteasome pathway. (A) An overview of the three enzymatic 
activities involved in ubiquitin-mediated proteolysis. (B) Components of the CRL1 (SCF) and 
CRL4 E3 ubiquitin ligase complexes. 
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with a number of substrate recognition factors (SRFs) (reviewed in (Petroski and Deshaies 
2005; Deshaies and Joazeiro 2009; Abbas and Dutta 2011).  Substrate specificity is 
afforded by the large number of these SRFs; for instance, CRL1 relies on 69 F-box proteins, 
while CRL4 uses ~60 DCAFs, allowing for the formation of a wide variety of E3 ligase 
complexes to control the degradation of different cell cycle regulators (Bennett et al. 2010; 
Craney and Rape 2013; Jin et al. 2004). 
Common mechanisms regulating E3 ligase activity and substrate recognition 
 As another important aspect to cell cycle control, ubiquitination reactions catalyzed 
by E3 ligase complexes must occur at the proper time and place.  This regulation often 
involves modification of substrates or E3s as a prerequisite for the ubiquitination reaction, 
and some of these mechanisms are discussed below: 
Post-translational modifications (PTMs) of substrates 
 Often, substrates of E3 ligase complexes are not constitutively degraded, but only in 
response to a particular signal.  One way in which this is accomplished is through post-
translational modification of the substrate degron motif.  As an example, Cdk2 
phosphorylates the replication factor Cdc10 dependent transcript 1 (Cdt1) at residue T29 as 
a prerequisite for recognition by the E3 ligase SCFSkp2 during S phase (Takeda et al. 2005).  
Hydroxylation (Ivan et al. 2001) and sumoylation (Perry et al. 2008) of degron sequences 
can also promote substrate ubiquitination.  Interestingly, phosphorylation of degron 
sequences can also inhibit substrate recognition by E3 ligases.  For instance, 
phosphorylation by cyclin E-cdk2 protects cell division cycle 6 (Cdc6) from proteolysis by 
preventing its association with the anaphase-promoting complex (Mailand and Diffley 2005).  
PTMs affecting substrate recognition do not necessarily have to occur within degron 
sequences.  For example, our lab showed that phosphorylation of Cdt1 at its c-terminus by 
stress-activated mitogen-activated kinases (MAPKs) protects Cdt1 from binding CRL4Cdt2 at 
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its N-terminal degron (Chandrasekaran et al. 2011).   
Cycles of NEDD8 attachment and removal to CRLs 
 In addition to modification of substrates, the catalytic core of E3 ligases themselves 
can be regulated to further control ubiquitination during cell cycle progression.  One of the 
key regulators of CRL activity is attachment of the ubiquitin-like protein NEDD8 to the cullin 
scaffold (Osaka et al. 2000; Sakata et al. 2007).  Neddlyation induces a conformational 
change in the cullin that increases the activity of the CRL, while also impeding the activity of 
Cand1, an enzyme that promotes the turnover of CRL-receptor complexes to facilitate SRF 
exchange (Pierce et al. 2013; Liu et al. 2002; Wu et al. 2013).  On the other hand, 
neddylation can be removed from cullins by the COP9-signalosome (CSN) (Lyapina et al. 
2001; Cope et al. 2002).  Deneddylation is blocked when the CRL is actively engaged in 
ubiquitination reactions, as the CSN cannot effectively recognize CRLs in these 
circumstances (Duda et al. 2008).  In this way, E3 activity is controlled during the cell cycle 
via cycles of neddylation and deneddlyation.  Acute inactivation of the NEDD8-E1 enzyme 
with the small molecule MLN4924 leads to rapid loss of all modified cullins and is frequently 
used in experimental manipulations to disrupt CRL targeting (Soucy et al. 2009; Lin et al. 
2010).   
Changes in substrate specificity promote sequential protein turnover by APCCdc20  
 One particular E3 ligase, APCCdc20, is unique in that it sequentially targets its cohort 
of substrates to promote the metaphase/anaphase transition during mitosis.  This activity is 
largely dependent on the status of the spindle assembly checkpoint (SAC), which inhibits 
APC/C activity during early mitosis. The SAC helps ensure proper chromosome segregation 
by preventing anaphase onset until chromosomes are properly aligned on the mitotic spindle 
(reviewed in (Musacchio and Salmon 2007). When the SAC is active, a Mitotic Checkpoint 
Complex (MCC) (comprised of BubR1, Mad2, Bub3, and Cdc20) binds to and inhibits the 
8                                                                                                                                     
APC/C (Herzog 2009).  Within this form of the APC/C, Cdc20 binds in a different orientation 
than it does within the APC/CCdc20 complex that drives sister chromatid separation during 
anaphase.  These differences in Cdc20 binding to APC/C depending on whether the SAC is 
active vs. inactive results in the degradation of some substrates (such as Cyclin A) before 
others promoting anaphase onset (like securin and Cyclin B1) (Izawa and Pines 2011; Tian 
et al. 2012).  Additional determinants of APC/C substrate degradation ordering have been 
uncovered recently in budding yeast, including the dependence of Clb5 on its Cdc20-binding 
“ABBA” motif and interaction within the Cdk1-Cks1 complex for early degradation. Cdk1-
dependent phosphorylation of securin and Dbf4 also contributes to their relatively delayed 
degradation (Lu et al. 2014).  The combination of these factors causes the same E3 ligase 
to recognize its substrates at different times in mitosis, resulting in a particular order of 
protein turnover to promote mitotic progression.  At the time of this study, this was the only 
E3 ligase known to sequentially target its substrates in this way, although we speculate that 
there are likely others (see Unanswered questions). 
Mechanism of replication-coupled destruction via CRL4Cdt2 
 The main focus of Chapter 2 of this dissertation is ubiquitin-mediated proteolysis by 
the E3 ubiquitin ligase CRL4Cdt2.  Substrate targeting by this E3 is unique in that it is linked 
specifically to the process of replication during S phase (Figure 1.3A).  Some of the first 
evidence for this was discovered while investigating the regulation of the origin licensing 
factor Cdt1.  Studies in mammalian cells (Nishitani et al. 2004) and Xenopus egg extracts 
(Arias and Walter 2005) showed that Cdt1 destruction occurred in S phase independently of 
geminin, an inhibitor of Cdt1 function (Wohlschlegel et al. 2000; Cook et al. 2004; Lutzmann 
et al. 2006).  It was further shown that Cdt1 is degraded by ubiquitin-mediated proteolysis 
during a single round of DNA replication in Xenopus egg extracts, suggesting a replication-
dependent mechanism (Arias and Walter 2005).  Replication-coupled proteolysis occurs not 
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only during S phase replication, but also during DNA repair synthesis in response to several 
damaging agents (Ralph et al. 2006; Higa et al. 2003; Jin et al. 2006; Sansam et al. 2006).  
Importantly, proteolysis by CRL4Cdt2 in response to DNA damage is dependent on the DNA 
synthesis step during the repair process and not the DNA damage response, as the 
checkpoint kinases ataxia telangiectasia mutated (ATM) and ataxia telangiectasia mutated 
and Rad3 related (ATR) are not required (Higa et al. 2003; Arias and Walter 2006; Centore 
et al. 2010). 
PCNA serves as the platform for replication-coupled destruction by CRL4Cdt2 
Subsequent experiments then probed the mechanism for replication-coupled 
destruction via CRL4Cdt2.  Cdt1 destruction was shown to be dependent on its interaction 
with Proliferating Cell Nuclear Antigen (PCNA), the processivity factor for DNA polymerases 
and , on chromatin (Arias and Walter 2006; Senga et al. 2006).  Cdt1 and other 
substrates of CRL4Cdt2 interact with PCNA through a PCNA interaction protein motif (PIP) 
box, which binds a hydrophobic pocket within the interdomain connector loop and C-
terminus of PCNA (Gulbis et al. 1996).  The PIP box within the substrate is critical for 
replication-coupled proteolysis both during S phase and during DNA repair synthesis (Arias 
and Walter 2006; Nishitani et al. 2006; Hu and Xiong 2006; Senga et al. 2006).  
Furthermore, recognition of substrates by CRL4Cdt2 depends on the prior binding of 
substrates on chromatin-bound PCNA, since if steps upstream of PCNA loading are 
blocked, CRL4Cdt2-mediated proteolysis cannot occur (Arias and Walter 2005, 2006; Havens 
and Walter 2009; Chandrasekaran et al. 2011).  Also, CRL4Cdt2 itself is recruited to 
chromatin during S phase and during DNA repair (Ishii et al. 2010; Jin et al. 2006), and 
CRL4Cdt2-mediated destruction only occurs when Cdt1 binds DNA-bound PCNA but not 
soluble (free) PCNA (Havens and Walter 2009).  Taken together, these results suggest a 
model whereby Cdt1 uses its PIP box to dock onto chromatin-bound PCNA, followed by  
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Figure 1.3. 
 
Figure 1.3.  Mechanism for replication-coupled destruction of CRL4Cdt2 targets. (A) 
Ubiquitin-mediated proteolysis via the E3 ubiquitin ligase CRL4Cdt2 is S phase specific. (B) 
The mechanism for CRL4Cdt2 targeting involves DNA loading of PCNA, substrate recruitment 
via a PIP degron sequence (Cdt1 is used as an example), followed by CRL4Cdt2 recognition 
of PCNA-bound substrates and subsequent proteolysis. 
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recognition by CRL4Cdt2, and finally ubiquitin transfer from the E2, leading to proteolysis 
(Figure 1.3B). 
Characteristics of the PIP degron sequence necessary for CRL4Cdt2 targeting 
 Many proteins contain PIP boxes that are not destroyed by CLR4Cdt2, begging the 
question of what distinguishes bona fide CRL4Cdt2 substrates from these other PIP box-
containing proteins.  It was later discovered that CRL4Cdt2 substrates contain specialized PIP 
degron sequences, which are comprised of both a PIP box as well as other key residues 
important for binding to either PCNA or Cdt2, indicated in the alignments shown in Figure 
1.4, (see also Figure 2 of (Havens and Walter 2011).  These residues include a “TD” motif in 
the vast majority of CRL4Cdt2 substrates, which confers tight binding of substrates to PCNA 
along with PIP box residues (Warbrick et al. 1997; Havens and Walter 2009).  The second 
important element distinguishing the PIP degron is a basic residue at the +4 position 
downstream from the PIP box (also called “B+4”).  Importantly, mutation of this residue was 
shown to block CRL4Cdt2 binding to Cdt1, without affecting the interaction between Cdt1 and 
PCNA (Havens and Walter 2009; Michishita et al. 2011).  Another feature of the PIP degron 
sequence is that it is transferable to heterologous substrates. Elegantly, it was shown that 
introduction of these key “TD” and “B+4” motifs into the PIP box of flap structure-specific 
endonuclease 1 (Fen1) resulted in its conversion to a CRL4Cdt2 substrate, even though Fen1 
is not normally targeted by CRL4Cdt2 (Havens and Walter 2009).  This portable nature of the 
PIP degron was taken advantage of in a variety of experiments in Chapter 2. 
 In addition, other residues were shown to be important for substrate interactions with 
PCNA and Cdt2.  For instance, the “B+3” residue is also a key degron residue, as alanine 
substitution of this residue inhibited HsCdt1 destruction (Michishita et al. 2011).  Also, 
substrates with internal or C-terminal PIP degron sequences contain a cluster of basic 
residues upstream of the PIP box (see Figure 1.4); mutation of these residues is important  
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Figure 1.4. 
 
 
 
Figure 1.4.  Alignment of PIP degrons of key CRL4Cdt2 substrates.  Shown are 
alignments of degron sequences from flies (Dm), humans (Hs), and frogs (Xl). Green 
residues mediate PCNA interaction and blue and magenta residues mediate Cdt2 
interaction.  See also Figure 2 from (Havens and Walter 2011). 
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for CRL4Cdt2 binding, but only when the B+4 residue is also mutated (Havens et al. 2012).   
Finally, an acidic residue in PCNA was identified (Asp-122), which is critical for CRL4Cdt2 
recruitment to chromatin, but not substrate interaction with PCNA (Havens et al. 2012).  
Likely, this is not an exhaustive list of important degron residues, and our studies in Chapter 
2 suggest that there are probably other key residues for efficient PCNA and CRL4Cdt2 
binding. 
Substrate ubiquitylation and beyond:  E2 selection and the role of the p97 ATPase 
 As an additional means to regulate CRL4Cdt2 substrate specificity, CRL4Cdt2 uses two 
different ubiquitin-conjugating enzymes (UBCs or E2s) to target different substrates.  In a 
recent study, it was shown that the UBE2G family of UBCs is important in the degradation of 
Cdt1, whereas UBCH8 is used in the degradation of the CDK inhibitor p21 and the histone 
H4 lysine 20 methyltransferase PR-Set7 (Shibata et al. 2011).  In Chapter 2, we also 
investigate the importance of E2 selection in the temporal regulation of CRL4Cdt2 targeting in 
collaboration with Anindya Dutta’s lab (University of Virginia).  
 Once ubiquitylated by CRL4Cdt2, substrates need to be removed from chromatin for 
delivery to the proteasome.  Recently, the ATPase p97 was implicated in this process (Franz 
et al. 2011; Raman et al. 2011).  A genome-wide screen showed that p97 is among the 
factors needed for Cdt1 ubiquitination following UV treatment (Raman et al. 2011).  Cells 
treated with siRNA against p97 accumulate polyubiquitinated Cdt1 and on chromatin, 
suggesting that p97 acts downstream of the ubiquitination reaction and is required for 
removal of ubiquitinated substrates from chromatin for subsequent proteasomal degradation 
(Raman et al. 2011).  Whether the timing or efficiency of this process is different between 
CRL4Cdt2 substrates has not been directly investigated, however. 
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Regulation of the CRL4Cdt2 E3 ligase complex 
 To further regulate CRL4Cdt2 targeting, the activity and stability of the E3 ligase 
complex itself is also dynamically controlled during the cell cycle.  As mentioned previously, 
a hyper-phosphorylated form of Cdt2 localizes to chromatin during S phase and following 
UV irradiation to facilitate the ubiquitylation of substrates on chromatin-bound PCNA (Ishii et 
al. 2010).  Our lab also showed that a CDK1-dependent mechanism interferes with Cdt2 
recruitment to chromatin beginning in late S phase, allowing for the stabilization of CRL4Cdt2 
substrates at the S/G2 transition (see Appendix and (Rizzardi et al. 2014)).  Finally, two 
independent studies showed that Cdt2 is subject to ubiquitylation and degradation by CRL1-
FBXO11 (Rossi et al. 2013; Abbas et al. 2013b).  Regulation of Cdt2 by CRL1-FBXO11 has 
been implicated in coordinating cell cycle exit and the cellular response to TGF-(Rossi et 
al. 2013; Abbas et al. 2013a). 
Biological importance of CRL4Cdt2-mediated degradation 
 Although the current list of confirmed CRL4Cdt2 substrates is relatively short, 
replication-coupled destruction via this E3 is quite important for proper S phase progression, 
and deregulation of CRL4Cdt2 has been implicated in a wide variety of human cancers (Ueki 
et al. 2008; Liu et al. 2009; Lee and Zhou 2010).  In this section, I will discuss the 
importance of CRL4Cdt2 substrate degradation during three major cellular processes: (1) 
DNA replication, (2) DNA repair, and (3) G1/S phase progression.  The cellular roles of 
CRLCdt2 targets and the consequences of their deregulation are summarized in Table 1.1. 
An overview of DNA replication origin licensing and firing 
 To replicate large eukaryotic genomes in a relatively short amount of time in S 
phase, DNA replication initiates from thousands of distinct sites called origins.  Origins are 
prepared for replication by the assembly of a multi-protein complexes called pre-replication 
complexes (pre-RC).  Pre-RC assembly begins in telophase and continues as cells progress 
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through G1 (Dimitrova et al. 2002).  Only origins with fully assembled pre-RCs are 
competent, or “licensed” for replication.  These licensed origins are in a poised but inactive 
state in G1, but do not initiate replication (or “fire”) until S phase begins (Figure 1.5A).  It is 
critical that this licensing step is restricted to G1 phase, as re-licensing can result in the 
generation of multiple replication forks on the same DNA strand, leading to DNA re-
replication.  Re-replication in turn promotes double strand breaks, genome instability, and 
ultimately tumorigenesis (Davidson et al. 2006; Xouri et al. 2004; Arentson et al. 2002) 
(Figure 1.5B).  On the other hand, insufficient origin licensing in G1 can result in replication 
forks having to travel excessive distances in the process of replication, leading to fork 
collapse and DNA damage (Nevis et al. 2009; Shreeram et al. 2002; Teer et al. 2006) 
(Figure 1.5C).   
 Origin licensing occurs in a step-wise process involving several proteins, shown in 
Figure 1.6.  First, the six-subunit origin recognition complex (ORC), comprised of subunits 
Orc2-6, recognizes and binds to an origin of replication.  Orc then recruits the replication 
factor cell division cycle 6 (Cdc6).  The combined ATPase activity of both ORC and Cdc6 is 
necessary to then promote loading of the replicative helicase complex onto DNA (Randell et 
al. 2006; Bowers et al. 2004).  The core replicative helicase, the Mini-Chromosome 
Maintenance (MCM) 2-7 complex, is recruited to origins by binding to the replication factor 
Cdt1 (Nishitani et al. 2000; Cook et al. 2004).  Cdt1 itself has no enzymatic activity, but 
delivers MCMs to chromatin-bound Cdc6 and ORC, which both hydrolyze ATP to load 
MCMs onto DNA (Randell et al. 2006).  ATP hydrolysis also releases Cdt1 to recruit 
additional MCM 2-7 hexamers (Randell et al. 2006).  MCMs are loaded as head-to-head 
double hexamers during pre-RC formation (Remus et al. 2009; Evrin et al. 2009), with 
multiple rounds of MCM loading per origin (Edwards et al. 2002).  Once loaded onto DNA, 
chromatin-bound MCM complexes mark origins as “licensed”, and replication can proceed  
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Figure 1.5. 
 
Figure 1.5.  Normal replication and consequences of deregulated origin licensing.  (A)  
During normal replication, origins are licensed during G1 (grey diamonds), but do not initiate 
replication or “fire” until S phase begins (yellow diamonds). Replication is completed by G2 
phase. (B)  Re-licensing events during S/G2 can lead to re-replication, which in turn 
promotes DNA damage, genome instability, and cell death. (C) Incomplete licensing during 
G1 can result in incomplete replication, which can also lead to fork collapse, cell death, and 
genome instability. 
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Figure 1.6. 
 
Figure 1.6.  Mechanism for MCM helicase loading in G1 phase.  Pre-RC assembly 
begins with ORC binding to origin DNA, followed by Cdc6 binding to ORC, and MCM 
recruitment by Cdt1. ATP hydrolysis by ORC and Cdc6 then load the MCM helicase onto 
DNA, which simultaneously releases Cdt1 to recruit additional MCM hexamers. Loading of a 
second hexamer yields a MCM double hexamer that is competent for replication.  Following 
MCM loading, other factors involved in the licensing and are removed by various 
mechanisms to avoid re-replication. 
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from these origins once the helicase is activated upon S phase entry.  At this point the 
replication factors ORC, Cdc6, and Cdt1 are dispensable (Donovan et al. 1997; Rowles et 
al. 1999), and their participation in further licensing is inhibited by several overlapping 
mechanisms to prevent re-replication (including CRL4Cdt2-mediated proteolysis). 
 Upon the G1/S transition, a rise in S-phase CDK (both Cdk2 and Cdk1) activity, as 
well as Cdc7/Dbf4 (DDK) activity, results in the recruitment of additional replication initiation 
factors needed for complete replisome formation (involving assembly of the Cdc45-GINS-
MCM2-7 (CMG) complex) and helicase activation (reviewed in (Labib 2010; Machida et al. 
2005; Tognetti et al. 2014).  At the same time, however, S phase CDK activity also blocks 
further licensing activity at origins that have already fired (Hua et al. 1997; Wheeler et al. 
2008).  In this way, S phase CDKs both positively and negatively affect DNA replication in S 
phase.  Interestingly, the number of replication origins that are licensed in G1 greatly 
exceeds the number that actually fire in S phase (Edwards et al. 2002; Mahbubani et al. 
1992; Rowles et al. 1996).  It is proposed that these excess licensed origins (also referred to 
as “dormant” origins) serve as a backup mechanism to ensure that a sufficient number or 
origins fire in S phase, particularly during replication stress (Ibarra et al. 2008; Ge et al. 
2007; Woodward et al. 2006).  Furthermore, licensed origins do not fire synchronously, 
instead firing at various times in S phase (reviewed in (Aparicio 2013). 
 Once helicase unwinding of origin DNA occurs, DNA polymerase /primase is 
recruited, which synthesizes a ~10 nt ribonucleotide primer, followed by a ~30 nt extension 
with deoxynucleotides.  The RNA-DNA primer is then displaced by replication factor C 
(RFC), which in turn recruits PCNA.  PCNA encircles DNA and serves as the processivity 
factor for DNA polymerase , allowing for subsequent DNA synthesis (Maga and Hubscher 
2003). 
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 Several overlapping mechanisms tightly control the MCM loading reaction to ensure 
that origins are licensed and replication initiates once and only once per cell cycle, that are 
reviewed extensively elsewhere (Arias and Walter 2007; Machida et al. 2005; Blow and 
Dutta 2005).  The levels and activities of the licensing factors Cdc6, Cdt1, and ORC 
subunits peak at different times in the cell cycle, allowing only two short windows when 
licensing can occur.  The first window occurs at the end of mitosis, before rising APCCdh1 
activity in G1 targets Cdc6 for degradation (Petersen 2000; Méndez and Stillman 2000).  
The second licensing window occurs when Cdc6 is stabilized by cyclin E-Cdk2 
phosphorylation of serine 54 (Mailand and Diffley 2005), but before Cdt1 is degraded in 
early S phase by ubiquitin-mediated proteolysis (see next section).  Also in early S phase, a 
member or the ORC complex, Orc1, is degraded or inactivated (Li and DePamphilis 2002; Li 
et al. 2004).  In mammalian cells, Cdc6 is exported from the nucleus during S phase, which 
involves a two-step mechanism:  First, Gcn5 acetylates Cdc6 at lysines 92, 105, and 109 
(Paolinelli et al. 2009), and this acetylation is prerequisite for phosphorylation of Cdc6 at 
residue serine 106 by cyclin A-Cdk2, leading to its export to the cytoplasm (Petersen et al. 
1999; Jiang et al. 1999).  Additionally, levels of the inhibitor geminin rise in S phase, which 
prevents Cdt1 licensing activity (Wohlschlegel et al. 2000; Lee et al. 2004; Cook et al. 2004; 
Lutzmann et al. 2006).  Finally, proteins involved in origin licensing and DNA replication 
control are transcriptionally regulated during the cell cycle and targeted for degradation by 
E3 ubiquitin ligases.  The remainder of this section will cover the role of the E3 ligase 
CRL4Cdt2 specifically in controlling the process of DNA replication. 
Prevention of re-replication by CRL4Cdt2-mediated degradation of Cdt1 and PR-Set7 
 One of the main roles of CLR4Cdt2 targeting is to guard against re-replication through 
degradation of Cdt1 (Nishitani et al. 2004; Arias and Walter 2005; Senga et al. 2006; 
Nishitani et al. 2006) and the histone methyltransferase PR-Set7 (Jørgensen et al. 2011; 
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Centore et al. 2010; Oda et al. 2010; Abbas et al. 2010).  Cdt1 destruction primarily prevents 
its further participation in origin licensing activity during S phase and during DNA damage 
repair.  It has been shown in many different model organisms that impairment of Cdt2 
targeting of Cdt1 results in high levels of re-replication and genome instability (Vaziri et al. 
2003; Arentson et al. 2002; Tatsumi et al. 2006; Lovejoy et al. 2006).  Cdt1 levels are also 
controlled by the E3 ligase SCFSkp2 during S phase, which requires prior cyclin A-CDK2-
mediated phosphorylation of Cdt1 on residue T29 (Takeda et al. 2005; Nishitani et al. 2006).    
While both CRL4Cdt2 and SCFSkp2 are responsible for Cdt1 degradation in S phase, the 
relative contribution of each of these E3 ubiquitin ligases to re-replication prevention is still 
unclear (see Unanswered questions). 
 Depletion of Cdt1 from mammalian cells using small interfering RNA (siRNA) inhibits 
MLN4924-induced re-replication, but only partially (Lin et al. 2010).  This result suggests 
that CRL4Cdt2 inactivation stabilizes a different target protein that contributes to this re-
replication phenotype.  This protein was soon identified as a CRL4Cdt2 target called PR-
Set7/Set8 (Jørgensen et al. 2011; Oda et al. 2010; Abbas et al. 2010; Centore et al. 2010).  
Origin licensing onset coincides with an increase in histone H4 Lys 20 monomethylation 
(H4K20me1) deposited by the PR-Set7 methyltransferase at replication origins.  Artificial 
tethering of PR-Set7 to a non-origin genomic locus is sufficient to induce pre-RC formation 
on chromatin (Tardat et al. 2010).  The H4K20me1 mark deposited by PR-Set7 during G2 
and mitosis is also important to promote proper chromosome condensation. Inactivation of 
Set8 causes many aberrant phenotypes, including failed mitotic progression, gross 
chromosomal decondensation, and spontaneous DNA damage (Karachentsev et al. 2005; 
Houston et al. 2008; Rizzardi et al. 2014).  Conversely, expression of Set8∆PIP, which cannot 
be degraded by CRL4Cdt2, results in premature chromosome compaction and abnormal H4 
methylation, which also lead to G2 arrest and increased DNA damage (Centore et al. 2010; 
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Tardat et al. 2010; Abbas et al. 2010; Jørgensen et al. 2011) Thus, by coordinating PR-Set7 
levels during the cell cycle, CRL4Cdt2 targeting helps prevent the occurrence of re-replication 
and facilitates chromosome compaction prior to mitosis.  Additionally, PR-Set7 is targeted by 
additional E3 ligases, APCCdh1 specifically during G1 (Wu et al. 2010) and SCFSkp2 (Yin et al. 
2008) during S phase, which further contribute to its dynamic cell cycle regulation.  
Importance of substrate degradation to replication progression 
 CRL4Cdt2 targeting also impacts replication progression in addition to controlling 
licensing.  One of the first confirmed substrates of CRL4Cdt2 was the S. pombe protein Spd1 
(Holmberg et al. 2005; Liu et al. 2005).  Spd1 is an inhibitor of the ribonucleotide reductase 
(RNR) enzyme, which synthesizes deoxyribonucleotide triphosphates (dNTPs).  It is 
proposed that CRL4Cdt2-mediated proteolysis of Spd1 promotes DNA synthesis during both 
repair and normal S phase replication by ensuring the availability of dNTPs.  Disruption of 
CRL4Cdt2 activity in S. pombe results in slow growth, defects in double strand break repair, 
and increased mutation rates, which are rescued (either partially or completely) in an Spd1 
deletion strain (Liu et al. 2005).  Lack of sequence conservation between RNR inhibitor 
proteins has impeded identification of mammalian counterparts for Spd1, so it is not yet 
clear whether this regulation by CRL4Cdt2 occurs in human cells (Vejrup-Hansen et al. 2014). 
 In mammalian cells, CRL4Cdt2 is also important for inhibition of p12, the fourth subunit 
of DNA polymerase  (Terai et al. 2013; Zhang et al. 2013), which is important for effective 
DNA replication and cell proliferation.  Degradation of p12 following UV-induced DNA 
damage was shown to be critical for impairing fork progression during the DNA damage 
response; cells expressing a stable form of p12 aberrantly undergo DNA synthesis in these 
circumstances, leading to decreased cell survival in response to DNA damage (Terai et al. 
2013).  CRL4Cdt2-directed degradation of p12 is also evident during a normal S phase, 
allowing the conversion of DNA polymerase 4 to 3. This 3 form of the polymerase can 
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more effectively engage in DNA repair processes during replication stress (Zhang et al. 
2013). 
Contribution of CRL4Cdt2-mediated proteolysis to DNA repair 
 Recently, CRL4Cdt2 targeting was shown to influence base excision repair (BER) 
through degradation of the repair factor thymine DNA glycosylase (TDG) (Slenn et al. 2014; 
Shibata et al. 2014).  TDG is involved in the BER process by removal of mispaired thymine, 
uracil, and certain modified cytosine residues when paired to guanine, creating an abasic 
site.  Also, TDG participates in DNA demethylation and thereby affects epigenetic regulation 
of gene expression (Wu and Zhang 2014).  TDG is degraded in a PIP-degron dependent 
manner in both X. laevis and mammalian culture systems, in response to both DNA damage 
and S phase entry (Slenn et al. 2014; Shibata et al. 2014).  Expression of a stable form of 
TDG (∆PIP) causes increased sensitivity to 5-FU (a uracil analog), as it leads to excessive 
production of abasic sites and increased checkpoint response (Shibata et al. 2014).  Thus, 
CRL4Cdt2 removal of TDG may help modulate TDG levels to prevent toxicity from excess 
TDG. 
 Another DNA repair process impacted by CRL4Cdt2-mediated ubiqutination is 
translesion synthesis (TLS), an error-prone DNA damage tolerance pathway that allows 
replicative bypass of DNA lesions using specialized polymerases.  When replication forks 
encounter sites of DNA damage, PCNA becomes monoubiquitinated, which in turn 
promotes recruitment of TLS polymerases (Bienko et al. 2010; Watanabe et al. 2004).  This 
monoubiquitination of PCNA is primarily controlled by the E3 ubiquitin ligase Rad18, 
although a recent study showed that CRL4Cdt2 also promotes PCNA monoubiquitination 
independently of Rad18 and in the absence of external damage (Terai et al. 2010).  It is 
thought that in this way, CRL4Cdt2 facilitates TLS associated with stresses encountered 
during normal replication progression.  Another way in which CRL4Cdt2 promotes TLS is 
23                                                                                                                                     
through degradation of p21.  Through its tight interaction with PCNA, p21 was shown to 
block TLS polymerase recruitment to sites of UV-induced DNA damage; thus, p21 
elimination by CRL4Cdt2 promotes efficient TLS polymerase exchange for replicative bypass 
(Mansilla et al. 2013; Soria et al. 2008).  On the other hand, CRL4Cdt2-mediated degradation 
can also restrict error-prone TLS by targeting one of the main TLS polymerases in C. 
elegans, PolIt is proposed that in this system, CRL4Cdt2-mediated degradation facilitates 
removal of  Polfrom the replication fork after its function in TLS (Kim and Michael 2008).  
Whether CRL4Cdt2 targeting regulates human Polis still unclear, however. One reason this 
regulation of TLS may be particularly important during early embryogenesis in C. elegans is 
that this system is particularly resistant to DNA damage-imposed cell cycle checkpoint 
activation; therefore early C. elegans embryos may be more reliant on DNA damage 
tolerance mechanisms for rapid replication of damaged DNA (Kim and Michael 2008).  
Control of the G1/S transition by degradation of p21 and dE2F1 
 In D. melanogaster, the CRL4Cdt2 E3 ubiquitin ligase also controls the G1/S transition 
by degrading the E2F1 transcription factor.  This “activator” E2F promotes the transcription 
of a variety of genes during G1 phase to promote S phase entry, and is cell cycle regulated.  
CRL4Cdt2 contributes to this cell cycle regulation by promoting dE2F1 destruction specifically 
during S phase, in a manner that is defendant on the PIP motif in dE2F1 and also the Dp 
dimerization partner, which is necessary for dE2F DNA binding (Shibutani et al. 2008).  
Furthermore, expression of a ∆PIP version of dE2F results in a variety of aberrant 
phenotypes, including a reduced G1 population, developmental defects, and apoptosis 
(Shibutani et al. 2008).  This CRL4Cdt2-dependent destruction of activator E2Fs does not 
appear to be conserved in other species, presumably because they have adapted other 
mechanisms to restrain E2F activity upon S phase entry. 
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 In Chapter 2 of this dissertation, we thoroughly investigate CRL4Cdt2 targeting of one 
of the major CKIs involved at the G1/S transition, p21.  p21 is targeted by CRL4Cdt2 both 
during S phase and during a DNA damage response (Abbas et al. 2008; Nishitani et al. 
2008; Kim et al. 2008) and purified CRL4Cdt2 can ubiquitinate p21 in vitro and in vivo (Abbas 
et al. 2008).  Additionally, p21 is degraded by SCFSkp2 during S phase (Bornstein et al. 2003) 
and APC/C in mitosis (Amador et al. 2007).  The relative contributions of SCFSkp2 and 
CRL4Cdt2 to the S phase degradation of p21 are currently unclear (see Unanswered 
questions). 
In contrast to other known substrates of CRL4Cdt2 discussed above, the reasons for 
replication-coupled destruction of p21 are not as well understood, however.  In C. elegans, 
p21 destruction, along with Cdt1 degradation, is implicated in restraining re-replication 
during S phase (Kim et al. 2007).  In this study, the authors attribute the persistence of p21 
with low CDK2 activity and failure to promote the nuclear export of the licensing factor Cdc6, 
ultimately contributing to increased re-replication (Kim et al. 2007).  Thus, p21 degradation 
may play a role in coordinating the onset of CDK2 activity to allow for Cdc6 phosphorylation 
and cytoplasmic export, among other events at the G1/S transition.  Through its interaction 
with PCNA, p21 has also been shown to block replication fork progression (Waga S, 
Hannon GJ 1994), so degradation of p21 at the G1/S transition may relieve this inhibition to 
control replication onset and maintain fork speed.  In support of this notion, while cells 
expressing low levels of p21 immediately progress through the cell cycle upon release from 
S phase arrest, cells with high p21 levels move much more slowly through replication in S 
phase (Gottifredi et al. 2004). More work clearly needs to be done to specifically show how 
ubiquitin-mediated proteolysis of p21 coordinates CDK levels and replication onset at the 
G1/S transition, which is a major topic of investigation in Chapter 2. 
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Table 1.1.  Summary of CRL4Cdt2 substrate functions and consequences of their 
deregulation 
 
 
Substrate Normal cellular function Phenotypes associated 
with deregulation 
Cdt1 Replication origin licensing Re-replication, genome 
instability 
Set8  Deposition of H4K20me1 to 
promote origin licensing in 
G1 and chromosome 
condensation during G2/M  
Re-replication, premature 
chromatin compaction in S 
phase, DNA damage, G2 
arrest 
S. pombe Spd1 Inhibits ribonucleotide 
reductase (RNR) to restrict 
dNTP production 
Slow growth rate, defects in 
DNA repair, increased 
mutation rate 
p12 Fourth subunit of DNA pol; 
necessary for fork 
progression 
Failure to inhibit fork 
progression following DNA 
damage, increased 
sensitivity to DNA damage 
TDG Base excision repair factor, 
DNA demethylation, 
epigenetic inheritance 
Increased sensitivity to 5-
FU; decreased cell 
proliferation 
C. elegans Pol TLS polymerase; replicative 
bypass 
Increased error-prone TLS, 
leading to mutagenesis 
p21 CDK inhibitor Increased re-replication in 
combination with Cdt1 
deregulation; deregulated 
CDK activity at G1/S?  
D. melanogaster E2F1 Activator E2F transcription 
factor; Expression of a 
variety of target genes 
needed for S phase 
Reduced G1, increased S 
phase population, 
apoptosis, developmental 
defects 
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Unanswered questions 
 Although much is known about the dynamic control of ubiquitin-mediated proteolysis 
during the cell cycle, and about the mechanism of CRL4Cdt2 targeting in particular, studies of 
this regulation particularly at transitions between cell cycle phases have been comparatively 
limited. Investigation of the temporal control of E3 ligase activity and substrate recognition at 
these critical transition points may enhance our understanding of how normal cell 
proliferation is coordinated, and how cancers may arise from deregulated cell cycle 
transitions. Some unanswered questions in the field, which we hope to address in our own 
studies, include the following: 
Do other E3 ubiquitin ligases besides APC/C degrade their substrates sequentially?  
Why is the order of substrate degradation important at cell cycle transitions? 
 
 At the time of this study, the APC/C was the only E3 ligase known to sequentially 
target its substrates.  The order in which APC/C targeting occurs is critical to ensure proper 
mitotic exit and cytokinesis (Elzen and Pines 2001; Lu et al. 2014; Izawa and Pines 2011; 
Lindon and Pines 2004).  For instance, the substrates Plk1 and Aurora A are degraded at 
different times as the APC/C switches from binding its activator Cdc20 and Cdh1.  
Expression of a non-degradable from of Plk1 causes a significant delay in mitotic exit 
(Lindon and Pines 2004).  It is highly likely that similar E3 ligase substrate ordering occurs to 
properly coordinate other cell cycle transitions.  In Chapter 2, we examine the temporal 
regulation of protein degradation mediated by one E3 ubiquitin ligase, CRL4Cdt2, and its 
importance to the coordination of S phase progression. 
Do E3 ligase substrates re-accumulate in a particular order? 
 Another interesting question is whether ordered protein re-accumulation, upon 
termination of E3 ligase activity, is similarly important to controlling cell cycle transitions.   In 
our own studies, we have observed that CDK-1-dependent inhibition of the CRL4Cdt2 E3 
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ubiquitin ligase results in the accumulation of its substrates at the end of S phase, and we 
propose that this build-up is necessary to prepare for the later functions of these proteins in 
mitosis and G1.  Interestingly, we have seen that these substrates also accumulate to 
different extents at late S phase time-points (Rizzardi et al. 2014).  More work is needed to 
further define ordered protein re-accumulation patterns and how they contribute to preparing 
for the next cell cycle phase. 
Why is CRL4Cdt2-mediated p21 destruction important to coordinating the G1/S 
transition?  How important are other CKIs to this process? 
 
 As alluded to in the Introduction, it is clear that p21 is a bona fide CRL4Cdt2 substrate, 
but the importance of its degradation to S phase progression is not well defined.  We 
speculate that p21 destruction at the G1/S transition may control the onset of S phase CDK 
activity needed for replication progression and several S phase events.  However, this 
regulation has not been shown experimentally.  In Chapter 2, we look more closely at the 
timing of p21 destruction and the consequences of manipulating the p21 degradation rate on 
replication efficiency in S phase.  In addition to p21, mammalian cells express two other 
CKIs, p27Kip1 and p57Kip2, which are cell cycle regulated.  The relative contributions of these 
CKIs to controlling the G1/S transition are also not well understood.  Whether these CKIs 
play redundant or separate roles from p21 in coordinating CDK activity will be an interesting 
topic of future investigation.   
 
  
28                                                                                                                                     
 
Chapter 2: Sequential Replication-Coupled Destruction at G1/S Ensures Genome 
Stability1 
Introduction   
A key regulatory mechanism ensuring unidirectional progression through the 
eukaryotic cell division cycle is the timely destruction of proteins via the ubiquitin-
proteasome pathway. The precise control of ubiquitin-mediated proteolysis is critical to many 
cellular processes including transcription, DNA replication, DNA repair, and chromosome 
segregation. Deregulated protein ubiquitylation can promote aberrant cell proliferation and 
genome instability (reviewed in (Teixeira and Reed 2013; Nakayama and Nakayama 2006). 
Ubiquitin-mediated degradation requires the selection of a protein substrate by an E3 
ubiquitin ligase. Several E3 enzymes recognize their targets via an amino acid binding motif 
in the substrate called a “degron.” For the cullin family of E3 ligases, degron binding 
facilitates ubiquitin transfer from an associated E2 enzyme to the substrate; successive 
ubiquitylations direct ultimate degradation by the 26S proteasome (Petroski and Deshaies 
2005; Nakayama and Nakayama 2006). Selectivity and timing of E3 ligase action by 
regulating degron recognition or E3 ligase activity allows oscillations in protein abundance to 
control key events.   
It is generally presumed that an individual E3 ubiquitin ligase targets its cohort of 
substrates simultaneously leading to their near-synchronous degradation. Countering this 
                                                 
1 Modified from Coleman KE, Grant GD, Haggerty RA, Brantley K, Shibata E, Workman BD, Dutta A, 
Varma D, Purvis JE, and Cook JG. 2015. Genes & Development, 29: 1734-1746.  
29                                                                                                                                     
notion however, several substrates of the anaphase-promoting complex/cyclosome 
(APC/C), the E3 ubiquitin ligase complex regulating mitotic progression, are degraded 
sequentially. Mammalian APC/CCdc20  triggers the degradation of substrates such as Nek2A 
and Cyclin A in prometaphase, well before the destruction of other APC/C substrates like 
securin and Cyclin B which occurs during metaphase (Elzen and Pines 2001; Hagting et al. 
2002). The mechanism distinguishing early vs. late substrates involves spindle assembly 
checkpoint-driven changes in how the Cdc20 substrate adapter interacts with APC (Izawa 
and Pines 2011). Likewise, budding yeast APC/C directs the degradation of the mitotic 
cyclin Clb5 before securin; in this instance, the distinguishing mechanism involves Cdk1-
mediated substrate phosphorylation near a Cdc20 binding motif (Lu et al. 2014). The 
ordered degradation of these mitotic proteins is essential for coordinated and accurate 
mitotic progression and cytokinesis (Elzen and Pines 2001; Lu et al. 2014; Izawa and Pines 
2011; Lindon and Pines 2004). It is not yet known if similar patterns of degradation occur at 
other cell cycle transitions. In particular, the temporal regulation of protein degradation 
during S phase entry is still poorly understood. We hypothesized that the events of S phase 
onset must be highly temporally controlled to properly coordinate replication onset, S phase 
progression, and precise genome duplication. 
To test this idea, we have investigated substrates of the CRL4Cdt2 E3 ubiquitin ligase, 
which triggers replication-coupled destruction of several lynchpin cell cycle proteins during S 
phase. In human cells, these substrates include Cdt1 (Arias and Walter 2005; Nishitani et al. 
2006; Senga et al. 2006) and PR-Set7 (Abbas et al. 2010; Centore et al. 2010; Oda et al. 
2010; Jørgensen et al. 2011), two factors critical to DNA replication origin licensing, the S 
phase cyclin-dependent kinase (CDK) inhibitor p21 (Abbas et al. 2008; Nishitani et al. 2008), 
the DNA polymerase delta subunit p12 (Zhang et al. 2013; Terai et al. 2013; Zhao et al. 
2014), the base excision repair enzyme thymine DNA glycosylase (TDG) (Shibata et al. 
2014; Slenn et al. 2014) and the nucleotide excision repair endonuclease xeroderma 
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pigmentosum group G (XPG) (Han et al. 2014). Each of these proteins is degraded by the 
same general mechanism which involves DNA loading of the sliding clamp processivity 
factor, proliferating cell nuclear antigen (PCNA), during DNA synthesis followed by binding 
of the substrate to PCNADNA via a PCNA-interacting motif  known as a PIP box (Figure 
2.1A) (Arias and Walter 2006; Senga et al. 2006). PIP boxes that confer replication-coupled 
destruction reside in specialized motifs termed PIP degrons that include additional residues 
necessary for recognition by CRL4Cdt2 (Havens and Walter 2009). The Cdt2 substrate 
adaptor subunit of CRL4Cdt2 recognizes a presumed composite surface consisting of the 
substrate PIP degron and specific residues from PCNADNA (Arias and Walter 2006; Havens 
and Walter 2009; Havens et al. 2012). Importantly, Cdt2 cannot stimulate substrate 
ubiquitylation unless the substrate is first bound to DNA-loaded PCNA, a requirement that 
couples substrate destruction directly to DNA synthesis (Havens and Walter 2009). 
Perturbations to replication-coupled destruction have profound effects on S phase 
progression and genome stability (Tardat et al. 2010; Arias and Walter 2005; Centore et al. 
2010; Abbas et al. 2010; Shibata et al. 2014; Zhang et al. 2013; Terai et al. 2013; Oda et al. 
2010; Arias and Walter 2006). 
The cell cycle functions of CRL4Cdt2 substrates vary widely, raising the possibility that 
they may need to be degraded at different times relative to one another to ensure orderly 
transition from G1 to S phase. Although the molecular mechanism of CRL4Cdt2-mediated 
degradation is well-characterized, it is still unclear whether all substrates are degraded with 
similar timing. It is also unclear if the relative timing of substrate destruction is important for 
the proper coordination of S phase progression. In this study, we provide the first direct 
evidence of ordered substrate degradation of CRL4Cdt2 substrates, and we show that the 
timing of substrate degradation is related to differences in the substrates’ PIP degron 
affinities for Cdt2. The sequential rather than simultaneous degradation pattern is essential 
to avoid replication stress during S phase.  
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Results 
CRL4Cdt2 substrates are degraded sequentially during early S phase.   
We first determined whether two CRL4Cdt2 substrates are degraded simultaneously 
or in a specified order at the G1/S transition. Toward that end, we quantified the change in 
Cdt1 and p21 concentrations in individual late G1 vs. early S phase cells. We synchronized 
HCT116 cells in mitosis by sequential thymidine and nocodazole blocks (Chandrasekaran et 
al. 2011), released from nocodazole, and pulse-labeled with BrdU prior to harvesting at time 
points corresponding to either G1 (2.5 h after release) or early S phase (4 h after release). 
We then immunostained these cells for endogenous Cdt1, p21, and BrdU incorporation. 
Both Cdt1 and p21 were readily detectable in G1, but notably Cdt1 was mostly degraded by 
early S phase whereas p21 was not (Figure 2.1B); p21 was more fully degraded later in S 
(Figure 2.2). We quantified the mean nuclear fluorescence intensities (Figure 2.1C) and 
scored nuclei for Cdt1 or p21 (Figure 2.1D). In cells with detectable Cdt1 or p21, the 
concentration of Cdt1 decreased more than 10-fold between G1 (2.5 h) and early S phase 
(4 h), but p21 levels only decreased 2-fold during that same time period  (Figure 2.1C). 
Furthermore, far fewer nuclei retained Cdt1 at the early S phase time point (24%) than 
retained p21 (70%).  Moreover, we detected a relatively low occurrence of BrdU-positive 
cells that co-stained for Cdt1 (9%), whereas BrdU/p21 double-positive cells were much more 
prevalent (30% of the total, and nearly half of the BrdU positive cells, suggesting that cells 
initiate DNA replication in the presence of p21 (Figure 2.1E). We note that at this single time 
point after synchronization not all cells have yet entered S phase cells which contributes to 
the Cdt1-positive cells in Figure 2.1D.  
A potential caveat to these immunofluorescence experiments was that the detection 
of endogenous Cdt1 and p21 required the use of different antibodies. To directly compare 
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Figure 2.1. 
 
Figure 2.1. CRL4Cdt2 substrates are degraded in a stereotypical order during early S 
phase. (A) The mechanism of cell cycle regulation of CRL4Cdt2 substrates requires PCNA 
DNA loading. (B) HCT116 cells were synchronized by sequential thymidine and nocodazole 
treatment and fixed at 2.5 h (G1) or 4 h (early S) after nocodazole release. Cells were 
labeled with BrdU 30 minutes prior to fixation and staining with the indicated antibodies. 
Scale bar = 5 m. (C) Average fluorescence intensities relative to G1 from 3 independent 
experiments; n = 15. (D) Percentage of nuclei positively stained by anti-Cdt1 or anti-p21; n = 
650. (E) Percentage of nuclei positively staining with the indicated antibodies from three 
independent experiments; n=200. Error bars indicate standard deviations. 
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Figure 2.2. 
 
 
 
Figure 2.2. Sequential destruction of CRL4
Cdt2
 targets during the G1/S transition. 
HCT116 cells were synchronized by sequential thymidine and nocodazole treatment and 
fixed at 2.5 h (G1), 4 h (early S), or 5.5 h (mid S) post nocodazole release.
 
Cells were 
labeled with BrdU 30 minutes prior to fixation and staining with the indicated antibodies. 
Scale bar = 10 m. 
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the rates of Cdt1 and p21 degradation using the same detection method, we generated 
fluorescent fusions. We fused cyan fluorescent protein (CFP, “mCerulean3”) to the C-
terminus of Cdt1 and yellow fluorescent protein (YFP, “Venus”) to the N-terminus of p21 
bearing a nuclear localization signal; these arrangements leave the regions of each protein 
that direct replication-coupled destruction unperturbed. We expressed them from a single 
bicistronic mRNA in which the two fusions are separated by a viral self-cleaving sequence 
from porcine teschovirus “P2A” (Kim et al. 2011) (Figure 2.3A).  We integrated the 
bicistronic cassette into U2OS cells at a single FRT locus under control of a doxycycline-
inducible promoter; the parent cells were engineered to constitutively express a histone 
H2B-mCherry fusion. Addition of doxycycline to the culture medium resulted in a dose-
dependent induction of both fusions, and importantly, no uncleaved protein was detectable 
even at the highest concentrations (Figure 2.3A). Induction with 20 ng/ml doxycycline 
produced YFP-p21 at close to endogenous levels, and Cdt1-CFP was moderately 
overproduced, so we selected this concentration for subsequent experiments (Figure 2.3A, 
lane 3). Importantly, both fusions showed the same stability as their endogenous 
counterparts (Figures 2.4A and 2.4B), and much higher levels of expression were required 
to produce detectable cell cycle perturbations (Figure 2.4C-E).  Based on our 
immunostaining results (Figure 2.1), we predicted that Cdt1-CFP would be consistently 
degraded before YFP-p21 and that in asynchronous populations we would observe YFP 
single positive cells but few CFP single-positive cells. To test this prediction, we imaged 
fixed asynchronous, unperturbed cells by fluorescence microscopy (Figure 2.3B). We 
identified nuclei and scored them as either YFP (p21) positive, CFP (Cdt1) positive, double 
positive, or double negative.  Among cells with detectable fluorescence expression, double-
positives were the most abundant class representing cells presumed to be in either G1 or 
G2 phase (31%). (Of note, we did not achieve 100% expression under these induction 
conditions meaning that we cannot conclude that all double-negative nuclei are in S phase.) 
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Strikingly however, YFP-p21 single positives represented a significant subpopulation (22%) 
whereas Cdt1-CFP single positive were exceedingly rare (0.3%) (Figure 2.3C). Altogether, 
these results suggest that the CRL4Cdt2 substrates Cdt1 and p21 undergo sequential rather 
than simultaneous degradation upon S phase entry during an unperturbed cell cycle. This 
finding prompted investigation into the molecular mechanism of this differential targeting. 
CRL4Cdt2 substrates are degraded sequentially during DNA repair synthesis. 
Since most DNA repair processes involve a DNA synthesis step, PCNA is loaded 
during DNA repair similar to its DNA loading during S phase. Consequently, CRL4Cdt2 
substrates are also degraded during DNA repair (Nishitani et al. 2008; Abbas et al. 2008; 
Senga et al. 2006; Abbas et al. 2010). We took advantage of this knowledge to induce 
synchronous PCNA loading and therefore simultaneous and robust replication-coupled 
destruction in otherwise asynchronous populations. We employed a semi-quantitative 
immunoblotting strategy to compare the relative degradation kinetics during DNA repair for 
CRL4Cdt2 substrates (Supplementary Figure 2.5 and Materials and Methods). To 
determine whether CRL4Cdt2-mediated destruction also occurs sequentially during DNA 
repair, we irradiated HCT116 cells with 20 J/m2 UV and monitored levels of three CRL4Cdt2 
targets  ̶  Cdt1, PR-Set7, and p21   ̶ in a time course. Similar to our analysis of the G1/S 
transition, Cdt1 was degraded dramatically faster than p21. By 15 minutes post-irradiation, 
Cdt1 was already more than 50% degraded, but p21 persisted much longer and was not 
substantially degraded until 60-120 minutes post-irradiation (Figure 2.6A, compare lanes 2 
and 5 to lane 1). The half-life of Cdt1 was only 9 min, but p21 was degraded with an 
average half-life of 53 min; the half-time for PR-Set7 degradation was intermediate at 23 min 
(Figure 2.6A). Importantly, we observed the same sequential relationship among the  
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Figure 2.3. 
 
 
Figure 2.3. Cdt1-CFP is degraded more rapidly than YFP-p21 in unperturbed cells. (A) 
Schematic of the bicistronic expression construct (top); Cdt1-HA-mCerulean3 (CFP) and 
Venus (YFP)-HA-p21 are produced from a single mRNA due to the presence of a viral self-
cleaving peptide “2A.” (Bottom) The resulting Cdt1 and p21 fusions were expressed from a 
single FRT locus in U2OS cells after doxycycline induction with the indicated concentrations 
for 20 h; the arrow marks the concentration used for imaging, and the asterisk marks the 
predicted size of the fusion in the absence of 2A-mediated cleavage. (B) A representative 
field showing double-negative, double positive and YFP (Venus) single positive cells; four 
single positive cells are marked with arrowheads. Scale = 100 µM. (C) Quantification of 
asynchronous Cdt1-mCerulean3 and Venus-p21-expressing U2OS cells. Averages from 
three fields of cells (n>150 per field) were scored as double-negative, double-positive, or 
single positive.    
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Figure 2.4. 
 
 
Figure 2.4. YFP-p21 and Cdt1-CFP fusion protein expression and validation. (A) 
Asynchronously proliferating U2OS cells expressing Cdt1-CFP-P2A-YFP-p21 were treated 
with 20 J/m2 UV and collected at the indicated times. The asterisk (*) marks the predicted 
position of the uncleaved fusion which is undetectable. (B) Quantifications of immunoblots 
from A. (C) U2OS cells were treated with the indicated concentrations of doxycycline to 
induce expression of YFP-p21 and Cdt1-CFP fusion proteins; fusions were detected by 
immunoblotting. (D) Cells treated with the indicated doxycycline concentrations as in (C) 
were analyzed by flow cytometry for DNA content. (E) Live cell movies of cells induced with 
the indicated doxycycline concentrations were analyzed for cell cycle length. Twenty cells (0 
ng/ml and 20 ng/ml) and 19 (75 ng/ml) cells were counted from one mitotic event to the next 
mitotic event.  Error bars indicate standard deviations. 
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CRL4Cdt2 substrates using other damaging agents such as oxidative damage (Figure 2.6B) 
and the radiomimetic bleocin (data not shown). Moreover, the degradation order was similar 
in other cell lines including U2OS and immortalized primary fibroblasts (NHF-hTERT) 
(Figure 2.6C). We also observed the same relative degradation order in cycloheximide-
treated cells (Figure 2.5B) and that p21 stably expressed from a heterologous promoter was 
degraded with the same kinetics as endogenous p21 (Figure 2.5B and 2.7A). These 
observations eliminated the possibility that the particularly slow p21 degradation reflected a 
contribution from p53-dependent p21 induction. We note that p21 is a well-known DNA 
damage-inducible gene making the degradation of p21 protein after DNA damage 
somewhat counter-intuitive. p21 induction and cell cycle arrest typically occurs at lower 
doses and at much later time points after DNA damage (Bendjennat et al. 2003; Pagano et 
al. 1994); in agreement with these previous studies, we also observed that p21 induction 
and cell cycle arrest only occurred 24 h after we treated HCT116 cells with 2-5 J/m2 UV 
(Figures 2.5C and 2.5D). On the other hand, CRL4Cdt2-mediated p21 destruction within 2-3 
hours was the predominant response to higher doses of UV (20 J/m2) used throughout this 
study. HeLa cells which are functionally p53-deficient also degraded Cdt1 more rapidly than 
they degraded PR-Set7 (Figure 2.5E). A recent study  implicated the Tripartite Motif 39 
(TRIM39) protein in regulating p21 degradation by blocking Cdt2 binding and inhibiting p21 
degradation (Zhang et al. 2012). We tested a mutant form of p21 that fails to bind TRIM39 
described in that study (p21-K153A), but observed no appreciable acceleration in its rate of 
degradation compared to the WT version (Figure 2.5F). Thus, we determined that slow p21 
degradation is common to many human cell lines and must be via a mechanism unrelated to 
de novo protein synthesis or interaction with TRIM39. 
The Cdt1 PIP degron confers an accelerated degradation rate. 
 Human Cdt1 codons 1-28 encode its single PIP degron, and when fused to a 
heterologous substrate, this sequence is sufficient to confer CRL4Cdt2-mediated degradation  
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Figure 2.5. 
 
Figure 2.5. p21 protein degradation is independent of DNA damage-inducible expression.  (A). 
Example of semi-quantitative immunoblot analysis of substrate degradation kinetics. (Lanes 1-6, (i):  
Two-fold serial dilutions of HCT116 cell lysate were immunoblotted for endogenous Cdt1 and tubulin 
(light and dark exposures are shown). Lanes 7-12, (ii): HCT116 cells were irradiated with 20 J/m
2
 UV, 
harvested at the indicated time points, and probed for endogenous Cdt1 and tubulin. Band intensities 
from multiple exposures were used to generate graphs of lysate loaded (i) and Cdt1 degradation (ii). 
(iii) Semi-log plot of % remaining values used for half-life determinations. (B) HCT116 cells were 
subjected to 20 J/m
2
 UV and treated with cycloheximide (10 µg/ml) immediately after irradiation 
(lanes 1-6) or left untreated (lanes 7-12). Cells were harvested at the indicated time points for 
immunoblot analysis. (C) Asynchronous HCT116 cells were treated with the indicated doses of UV 
and collected after 24 h for immunoblot analysis. (D) Cells treated as in (C) were analyzed by flow 
cytometry for DNA content. HCT116 cells stably expressing wild-type HA-tagged p21 used in Figure 
4A are included for comparison. (E) HeLa cells were subjected to a UV time-course and compared to 
HCT116 cells. (F) HCT116 cells expressing ectopic HA-p21 deficient for TRIM39 binding (K153A) 
were treated with 20 J/m
2
 and harvested at the indicated time-points for immunoblot analysis of 
ectopic and endogenous p21 levels. 
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Figure 2.6. 
 
 
 
 
 
Figure 2.6. CRL4Cdt2 substrates are degraded sequentially during DNA repair 
synthesis. HCT116 cells were treated with (A) 20 J/m2 UV or (B) 100 μM tert-butyl peroxide 
and harvested at the indicated times after treatment for immunoblot analysis. Non-specific 
bands serving as loading controls are indicated by asterisks (*). Quantifications of 
immunoblots from a minimum of three biological replicates of the UV time course are 
plotted. (C) NHF-hTERT cells (lanes 1-7) or U2OS cells (lanes 8-14) were treated with 20 
J/m2 UV and harvested at the indicated time points as in (A). Error bars indicate standard 
error of the mean (SEM). 
 
 
 
 
 
 
 
 
 
41                                                                                                                                     
(Senga et al. 2006; Rizzardi et al. 2014). Given our finding that Cdt1 is consistently the most 
rapidly degraded among the CRL4Cdt2 substrates tested, we sought to determine if the Cdt1 
PIP degron is sufficient to confer the fast kinetics of degradation. We therefore fused Cdt1 1-
28 to the N-terminus of an epitope-tagged p21 and compared this fusion to a 
correspondingly epitope-tagged WT p21. We generated stable HCT116 cell lines producing 
these fusions at near-endogenous levels and utilized the same UV irradiation strategy to 
induce synchronous replication-coupled destruction as in Figure 2.6. Firstly, the addition of 
an N-terminal HA epitope tag to p21 had no measureable effect on degradation kinetics; 
both endogenous and tagged p21 were degraded at the same rate and substantially slower 
than endogenous Cdt1 (Figure 2.7A). Second, constitutive expression of HA-p21 from a 
heterologous promoter had no effect on p21 degradation kinetics (Figure 2.5B and Figure 
2.7A) and did not alter cell cycle phase distribution (Figure 2.5C lane 6 and 2.5D). Strikingly 
however, the PIPCdt1-p21 chimera was degraded much more rapidly than either WT p21 or 
endogenous p21, and this chimeric protein more closely resembled the degradation kinetics 
of endogenous Cdt1 with a half-life of just 20 min (Figure 2.7B). A PIPCdt1-p21 chimera in 
which key amino acids of the Cdt1 PIP degron were mutated to alanine (PIPmCdt1-p21) was 
degraded with kinetics similar to both WT HA-p21 and endogenous p21 as expected 
(Figure 2.7C). Thus, addition of the Cdt1 PIP degron to the N-terminus of p21 is sufficient to 
confer accelerated p21 degradation. 
We considered several explanations for the rapid degradation of the PIPCdt1-p21 fusion:  
the addition of a second PIP degron, the N-terminal location of the PIP degron, or the PIP 
degron sequence itself. To test the idea that rapid degradation is achieved simply by the 
presence of two degrons, we disrupted the native p21 PIP degron sequence in the PIPCdt1-
p21 chimera leaving only the one Cdt1 PIP degron ,”PIPCdt1-p21PIPm”. We confirmed p21 
PIP degron impairment in a control experiment (Figure 2.8A and 2.8B).  The PIPCdt1-
p21PIPm fusion was still degraded faster than endogenous p21 (Figure 2.7D), indicating 
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that the presence of two degron sequences did not account for the accelerated degradation 
of the PIPCdt1-p21 fusion in Figure 2.7B. The native PIP degron sequences of Cdt1 and p21 
are located at either the N- or C-terminus of each protein respectively; thus, the relative 
location of the PIP degrons could impact accessibility to PCNA and/or CRL4Cdt2. Importantly, 
when we fused a second copy of p21’s PIP degron to its own N-terminus, this PIPp21-p21 
fusion was degraded slowly like endogenous p21 (Figure 2.7E).   Finally, we fused the p21 
PIP degron to an HA-tagged form of Cdt1 lacking its own native PIP degron. We confirmed 
that the tag did not disrupt WT Cdt1 degradation kinetics (Figure 2.7F) and that deleting 
Cdt1’s PIP degron stabilized Cdt1 independently (Figure 2.8C).  Cdt1 bearing a single PIP 
degron derived from p21 was degraded more slowly than WT Cdt1, particularly at later time 
points (Figure 2.7F). These experiments yield several important mechanistic insights: the 
PIP degron sequence itself carries intrinsic and transferable information dictating the 
degradation kinetics, the location of the PIP degron sequence has little impact on 
degradation kinetics, and an additional PIP degron sequence is insufficient to enhance the 
degradation rate. 
The accelerated degradation of the PIPCdt1-p21 fusion during DNA repair suggested that 
a similar fusion would be degraded with faster kinetics in early S phase since the same 
ubiquitylation pathway applies to both S phase and DNA repair. To test that idea, we fused 
YFP to the C-terminus of PIPCdt1-containing p21 and integrated this doxycycline-inducible 
fusion into U2OS cells expressing histone H2B-mCherry. As a control we integrated a YFP-
p21 fusion to create a separate cell line. The arrangement of these fusions was designed to 
avoid perturbing the relevant PIP degrons. Of note, high concentrations of doxycycline 
induced substantial p21 overproduction and G1 accumulation indicating that both fusions 
are likely active CDK inhibitors (Figures 2.9A and 2.9B), but cells can tolerate moderate 
p21 overproduction (e.g. from induction with 10-30 ng/ml) with no detectable change in in 
cell cycle phase distribution (Figure 2.9B). Moreover, the UV-triggered degradation of  
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Figure 2.7. 
 
Figure 2.7. The Cdt1 PIP degron confers accelerated degradation to p21 during DNA repair. (A) 
HCT116 cell lines were generated that stably produce (A) HA-tagged WT-p21, (B) HA-tagged PIPCdt1-
p21, (C) HA-tagged PIPmCdt1-p21 bearing inactivating mutations in the Cdt1 PIP degron, (D) HA-
tagged PIPCdt1-p21 fusion with the native p21 PIP degron inactivated, or (E) PIPp21-p21 with the native 
p21 PIP degron added to the N-terminus. (F) HA-tagged WT Cdt1 or Cdt1 lacking its native PIP 
degron (“Δ”) but fused to the p21 PIP degron was expressed from an inducible promoter in U2OS 
cells with 20 ng/ml doxycycline.. These cell populations were treated with 20 J/m2 UV and harvested 
at the indicated times for immunoblot analysis. Quantifications of immunoblots for ectopic and 
endogenous p21 and Cdt1 proteins are from two independent experiments; error bars indicate SEM.  
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Figure 2.8. 
 
 
Figure 2.8. Mutation of PIP degron sequences impairs CRL4
Cdt2
-mediated proteolysis. 
(A) Cells expressing ectopic HA-tagged p21 bearing alanine substitutions in p21 amino 
acids 146-150 were treated with 20 J/m
2
 UV and harvested at the indicated time-points for 
immunoblot analysis.  (B) Alignment of the PIP degron sequences from human Cdt1, PR-
Set7, and p21.  Basic residues are in magenta, hydrophobic residues in green, and the 
conserved T and D common to PIP degrons are in blue.  (C) Cdt1 15-546 lacking the native 
PIP degron and tagged at the C-terminus was expressed from a doxycycline-inducible 
promoter in U2OS cells (20 ng/ml doxycycline), then analyzed as in A. 
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PIPCdt1- p21-YFP was accelerated compared to normal YFP- p21 or endogenous p21 similar 
to the HA-tagged fusions in Figure 2.7B (Figure 2.9C).  
We induced expression of both p21 fusions to similar levels (10 ng/ml for WT and 30 
ng/ml for PIPCdt1-p21) and imaged unperturbed proliferating cells for at least 16 hours, 
capturing fluorescence images of histone H2B-mCherry and YFP-p21 every ten minutes 
(representative Supplementary videos 1 and 2). We subjected the videos to 
computational segmentation using the histone H2B-mCherry to mark and track nuclei and 
then automatically quantified the average fluorescence intensity of YFP in both lines (see 
Methods). Each set of fluorescence intensities was normalized from zero (minimum) to 1 
(maximum) for 50 cells that we selected for expression of the fusion and that underwent 
both mitosis and a complete degradation/re-accumulation cycle (i.e. S phase) within the 
recorded time. The dynamics of YFP-p21 degradation are shown for these cells as a heat 
map in Figure 2.10A with the first data point plotted for each cell corresponding to the video 
frame containing the cell division that produced that cell.  Fitting these in silico aligned 
traces for each cell to an inverse sigmoidal curve yielded Td, the time from mitosis to the 
half-point of degradation (Figure 2.10B). We then calculated the relative maximal rates of 
degradation from the slopes at each Td and noted that the degradation rate of the PIPCdt1-
containing fusion was more than 5 times that of the fusion bearing only the native p21 PIP 
degron. 
Differential recruitment of PCNA/Cdt2 by PIP degrons 
We next generated new degron fusions in which either the Cdt1 or p21 PIP degron plus 
a nuclear localization signal (NLS) was fused to glutathione-S-transferase (GST). These 
fusions created an artificial substrate for replication-coupled CRL4Cdt2-mediated proteolysis 
and had the added benefit of isolating the Cdt1 and p21 PIP degrons from their respective 
full-length proteins (Figure 2.11A). We monitored the degradation kinetics of the GST 
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fusions after UV irradiation as before and found that PIPp21-GST was degraded more slowly 
than PIPCdt1-GST, similar to the relationship between the endogenous proteins from which 
they were derived (Figure 2.11A).  
Two critical interactions for productive replication-coupled destruction are binding of the 
PIP degron to DNA-loaded PCNA (PCNADNA) and subsequent recruitment of CRL4 through 
substrate interaction with the substrate receptor, Cdt2. Differences in affinities for PCNADNA 
and/or Cdt2 could explain why proteins containing the Cdt1 PIP degron are consistently 
degraded before proteins with the p21 PIP degron. To test this idea, we produced the same 
PIPCdt1-GST and PIPp21-GST constructs in bacteria, isolated the recombinant proteins on 
glutathione beads and used them to retrieve PCNADNA and Cdt2 from sonicated chromatin 
fractions of human cell lysates. We had previously used this strategy to analyze interactions 
of full-length Cdt1 with PCNADNA and Cdt2 (Chandrasekaran et al. 2011). As controls we 
included a full-length GST-tagged p21 and a PIP mutant form of p21 which cannot bind 
PCNA, PIPmp21-GST (Rizzardi et al. 2014). As expected, the PIP mutant p21, unlike the WT 
p21, did not bind PCNADNA (Figure 2.12).  
First, although equal amounts of solubilized chromatin were incubated with the two PIP 
degron fusions, the p21 PIP degron retrieved approximately three times more PCNA than 
the Cdt1 PIP degron did under the same conditions (Figure 2.11B, compare lanes 3 and 
4). This tight binding of p21 to  PCNA is consistent with prior studies (Arias and Walter 2006; 
Gulbis et al. 1996). Surprisingly, even with this strong relative binding to PCNA, the p21 PIP 
degron did not recruit proportionately more Cdt2 (Figure 2.11B, compare lanes 3 and 4). In 
fact, PIPCdt1-GST retrieved more Cdt2 than PIPp21-GST did, despite holding 3-fold less 
PCNADNA (Figure 2.11B, lanes 3 and 4). The significantly better Cdt2 binding with PIPCdt1 
GST was most readily apparent when we directly compared equal levels of co-purified 
PCNA; PIPCdt1-GST bound more than 5-fold more Cdt2 than PIPp21-GST did for the same 
amount of co-purified PCNA (lanes 3 and 4, Figure 2.11C and D). Thus, the Cdt1 PIP  
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Figure 2.9. 
 
Figure 2.9. Validated YFP-p21 and PIPCdt1-p21-YFP fusion regulation and function. (A) 
Asynchronous U2OS cells expressing either YFP (Venus)-p21 or PIPCdt1-p21-YFP fusions 
were induced with the indicated concentrations of doxycycline and then subjected to anti-
p21 immunoblot analysis. (* indicates a non-specific band that serves as a loading control.)   
(B) Flow cytometry analysis of DNA content of cells expressing YFP fusion proteins shown 
in (A).  Doxycycline concentrations of each cell line used in the imaging analysis in Figure 5 
are underlined.  (C) Asynchronous U2OS cells expressing either YFP-p21 or PIPCdt1-p21-
YFP proteins (induced with 20 ng/ml doxycycline) were treated with 20 J/m2 UV and 
collected at the indicated times for immunoblot analysis. 
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Figure 2.10. 
 
 
 
Figure 2.10. The Cdt1 PIP degron confers accelerated degradation to p21 at G1/S. (A) 
Heat maps for the kinetics of YFP-p21 and PIPCdt1-p21-YFP degradation in 50 
asynchronously proliferating cells generated by high content live cell imaging. Expression 
was induced with 30 ng/ml doxycycline for YFP-WT-p21 and 10 ng/ml doxycycline for 
PIPCdt1-p21-YFP (see Supplementary Figure 5) and individual cell fluorescence intensity 
traces were computationally aligned to mitosis (t=0). Fluorescence intensities were 
normalized to individual minima and maxima (see Methods). (B) Data were fit to sigmoidal 
curves, and the average time for degradation from mitosis to the half minimum fluorescence 
intensity, “Td,” is marked with black dashed lines on both the heat maps and the plots. The 
slopes at Td are indicated. 
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Figure 2.11. 
 
Figure 2.11. The Cdt1 PIP degron binds more Cdt2 than the p21 PIP degron. (A) 
HCT116 cells stably expressing either Cdt1 PIP (aa 1-28) or p21 PIP (aa 137-164) fused to 
the N-terminus of GST were UV-treated and harvested for immunoblot analysis  at the 
indicated times. (B) PIP-GST fusion proteins were purified from E.coli lysates with 
glutathione-sepharose beads and incubated with sonicated chromatin fractions from UV-
irradiated 293T cells. Bound proteins were eluted in 2X SDS buffer and subjected to 
immunoblot analysis with the indicated antibodies. Lanes 2-4 contained equivalent amounts 
of GST fusions. (C) PIP degron-bound proteins were prepared as in (B), but loaded 
equivalently for co-purified PCNA. (D) Quantification of the relative amounts of bound PCNA 
and Cdt2, based on two independent experiments; error bars indicate standard deviations. 
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Figure 2.12. 
 
 
 
 
 
Figure 2.12. p21
PIPm
 (PIP degron mutant) fails to bind PCNA
DNA
.  (A) The indicated GST 
fusion proteins were purified from E.coli lysates with glutathione-sepharose beads and 
incubated with sonicated chromatin fractions from UV-irradiated 293T cells.  Bound proteins 
were eluted in 2X SDS buffer and subjected to immunoblot analysis after normalizing for 
bound GST. (B) Alignment of PIP degron sequences from human Cdt1, PR-Set7, p21 and 
p21
PIPm
. Positions previously shown to be important for CRL4
Cdt2
-mediated degradation are 
shown in red. 
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degron more efficiently recruits Cdt2, and this effect likely contributes to its accelerated 
degradation via the CRL4Cdt2 E3 ubiquitin ligase.  
We also considered a potential role for ubiquitin E2 utilization in the differential 
degradation of Cdt1 and p21.  Ubiquitylation by cullin E3 ligases is catalyzed by associated 
E2 ubiquitin-conjugating enzymes (UBCs), and our recent study showed that ubiquitylation 
of p21 and Cdt1 is carried out by different E2s: UBE2G1+UBE2G2 for Cdt1 and UBCH8 for  
p21 (Shibata et al. 2011). Different E2s may be responsible for the different degradation 
rates and further, exchanging the PIP degrons might have led to E2 switching. To test this 
hypothesis, we used RNAi-mediated depletion of the relevant E2s to determine if thePIPCdt1-
p21 fusion (diagramed in Figure 2.7B) relies on the E2 that normally targets Cdt1 (i.e. 
UBE2G1+UBE2G2). As shown in Figure 2.13A and 2.13B however, the PIPCdt1-p21 fusion, 
just like endogenous p21, was stabilized in UBCH8-depleted cells, whereas its typical 
accelerated degradation pattern was observed in both control and UBE2G1+UBE2G2-
depleted cells. Thus, we concluded that degradation of PIPCdt1-p21 still involves the same 
E2 as normal p21, arguing against an E2 switch. Substrate features separate from those 
directly responsible for E3 recruitment must control E2 specificity, but that discrimination 
plays little role in the rate of CRL4Cdt2-mediated degradation.  
Delayed p21 degradation facilitates normal S phase progression. 
We next sought to probe the physiological importance of sequential CRL4Cdt2 substrate 
degradation. Specifically we tested the consequences of imposing the early Cdt1 
degradation pattern on p21. For this purpose, we stably produced siRNA-resistant versions 
of the PIPCdt1-p21 and WT-p21 described in Figure 2.7 in HCT116 cells. We depleted 
endogenous p21 and analyzed cell cycle profiles by flow cytometric measurement of BrdU 
incorporation and DNA content (Figure 2.14A). Neither siRNA depletion of p21, nor stable 
expression of WT-p21 had a substantial effect on overall cell cycle distribution in these cells  
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Figure 2.13. 
 
Figure 2.13. The Cdt1 PIP degron fused to p21 is still a substrate for the p21-specific 
E2 (UBCH8).  (A) HCT116 stably expressing PIP
Cdt1
-p21 were depleted of UBCH8 or 
UBE2G1 +UBE2G2 as in Shibata et al. 2011.  Cells were treated with cycloheximide for 10 
min before 20 J/m
2
 UV irradiation, collected at the indicated times after UV treatment and 
then analyzed for ectopic and endogenous p21 by immunoblotting; GAPDH serves as a 
loading control.  (B) Immunoblot analysis of siRNA transfected cells to assess E2 depletion. 
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(Figure 2.14B), but we noted that p21 depletion caused an increase in a sub-population of 
cells of intermediate DNA content (i.e. S phase) that were not actively synthesizing DNA. 
We scored this population as “BrdUneg /S phase“, and following p21 depletion, there were 3x 
more BrdUneg/S phase cells compared to control cells. This phenotype was complemented 
by ectopic WT-p21 (without causing cell cycle arrest), but strikingly PIPCdt1-p21 cells still 
generated the BrdUneg /S phase subpopulation (Figure 2.14A and 2.14B). PIPCdt1-p21 was 
produced at levels similar to endogenous p21 in control RNA-treated cells which suggests 
that the phenotype of the PIPCdt1-p21 line is the kinetics of p21 degradation rather than 
insufficient p21 (Figure 2.14C).  
The increase in cells that reached mid-S phase but then stopped DNA synthesis 
(BrdUneg /S phase) suggested that premature p21 degradation leads to difficulty in 
maintaining active replication. If true, then these cells may experience higher than normal 
rates of endogenous DNA damage which could render them more sensitive to additional 
damage or replication stress. To test that idea more directly, we produced the same p21 
fusions as YFP-tagged forms (i.e. Figure 2.10) in U2OS cells and then challenged them to 
recover from a strong replication block. We depleted endogenous p21 (Figure 2.15A), and 
then held cells in hydroxyurea for 16 h to induce replication stalling. We immunostained for a 
marker of DNA damage often associated with replication stress, -H2AX, and found the 
expected high percentage of positively-staining cells in all HU-arrested populations (Figure 
7D and E). Releasing cells into fresh medium allowed S phase resumption within 12 h in 
cells expressing normal p21 as measured by both flow cytometry (Figure 2.15B) and 
elimination of -H2AX foci (Figure 2.14D and 2.14E). In contrast to both siRNA controls and 
p21-depleted cells complemented with WT-p21 however, p21-depletion caused 2-fold more 
retention of -H2AX signal 12 h after HU release (Figure 2.14D 12 h, and 2.14E). Strikingly, 
cells expressing PIPCdt1-p21 to similar levels as WT-p21 (Figure 2.15A) retained as much  
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Figure 2.14. 
 
Figure 2.14. Accelerating p21 degradation promotes replication stress. (A) Asynchronously 
growing HCT116 cell lines stably-expressing the indicated HA-tagged p21 fusions were treated with 
100 nM of control or p21 siRNA for 48 h. Cells were labeled for 1 h with BrdU and analyzed by flow 
cytometry with anti-BrdU antibody to detect DNA synthesis (y-axis) and with propidium iodide for DNA 
content (x-axis). Flow cytometry gating for distinguishing BrdU negative S phase cells is indicated in 
the schematic. Percentage of the total population in each gated cell cycle phase is indicated on the 
plots. (B) Percentage of BrdU negative/S phase cells in samples from (B); error bars indicated 
standard error of the mean. (C) Immunoblots of endogenous and ectopic p21 in (B). (D) U2OS cells 
producing the indicated p21-YFP fusions (induced with 10 ng/ml doxycycline) were treated with 2 mM 
HU for 16 h and subsequently released into fresh medium for 12 h, as indicated. Representative 
images (D) show -H2AX staining of cells for each condition, and the percentage of -H2AX positive 
cells is quantified in (E). Scale bar = 30 m. For quantifications > 200 nuclei from randomly-selected 
fields were counted for each condition, and error bars represent standard deviations from two 
independent experiments. p=<0.05 
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Figure 2.15. 
 
 
Figure 2.15. HU-mediated replication-coupled destruction and recovery. A) Immunoblot 
and (B) flow cytometry analysis of samples from HU arrest and release experiment in Figure 
7D. Cells were treated with 100 nM siRNA and 10 ng/ml doxycycline as indicated.  
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-H2AX signal as p21-depleted cells did (Figure 2.14C and D). Altogether, these results indicate that 
the normal delayed p21 degradation in early S phase contributes to robust replication progression 
during S phase. Furthermore, the absence of p21 during early S phase sensitizes cells to subsequent 
replication stress and DNA damage. 
Discussion 
 In this study we provide conclusive evidence that despite being subject to the same 
targeting mechanism, several substrates of the CRL4Cdt2 E3 ubiquitin ligase are degraded in 
a conserved and stereotypical order. In particular, p21 degradation is significantly delayed 
relative to Cdt1 (and PR-Set7) both during early S phase and during DNA repair. As a result, 
early S phase cells and cells beginning DNA repair lack Cdt1 but still have abundant p21. 
Several other studies (Nishitani et al. 2008; Shibata et al. 2011; Bendjennat et al. 2003; 
Zhang et al. 2013; Abbas et al. 2008, 2010) explored CRL4Cdt2 substrate degradation 
kinetics, and late p21 degradation is detectable in those studies but had not been 
investigated. We note also that these three proteins appear to re-accumulate at the end of S 
phase in reverse order relative to the order in which they are degraded (Nishitani et al. 2008; 
Rizzardi et al. 2014; Abbas et al. 2010).   
Based on our observations, early Cdt1 degradation relative to p21 in S phase is likely 
due to differences in the efficiency with which different PIP degrons recruit Cdt2 (Figure 
2.16A). It is not yet clear however why the Cdt1 PIP degron confers weaker PCNA binding 
but more efficient Cdt2 recruitment. Detailed structural information about the interaction of 
p21’s PIP degron with PCNA is available (Gulbis et al. 1996), and a collection of alanine 
substitutions at sites critical for PCNA binding or Cdt2 recruitment block replication-coupled 
destruction (Arias and Walter 2006; Havens and Walter 2009). Interestingly however, none 
of those previously-studied positions are significantly different between the p21 and Cdt1 
PIP degrons (Figure 2.8B). We presume that the substantially more efficient in vitro Cdt2 
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recruitment by the Cdt1 PIP degron is the major reason for faster Cdt1 degradation in vivo, 
but other mechanisms may also contribute. Among these factors are differences in 
ubiquitylation processivity as is observed among substrates of the APC/C (Rape et al. 
2006). Strikingly, p21’s PIP degron binds PCNADNA in vitro more efficiently than Cdt1’s PIP 
degron does (Figure 2.11). It is possible that the p21-PCNADNA interaction is in fact too tight 
for maximally-efficient degradation compared to other CRL4Cdt2 substrates, but this idea has 
not yet been explored. Tight PCNA binding by p21 has been suggested to compete with 
other PCNA binding proteins (Warbrick et al. 1997; Ducoux et al. 2001; Arias and Walter 
2006), and so we have considered the possibility that competition among PIP degrons 
contributes to their order of degradation. We have not observed however any evidence for 
competition effects at either the endogenous levels of CRL4Cdt2 substrates or when they are 
moderately overproduced.  For example the ~2-fold increase in PIP degron from the ectopic 
fusions in Figure 2.7A and 2.7B had no effect on the rates of endogenous Cdt1 and p21 
degradation. Thus we do not favor a model in which the higher affinity of Cdt2 for Cdt1 leads 
to slower p21 degradation strictly through competition for either PCNA or Cdt2. 
 By fusing Cdt1’s PIP degron to p21, we created a scenario in which p21 is expressed 
in G1 but degraded prematurely at the beginning of S phase rather than at the normal time 
well after S phase is underway. Interestingly, the consequences of accelerating the timing of 
p21 degradation are very similar to depleting cells of p21 altogether with respect to 
replication stress. The striking similarity of cells expressing the PIPCdt1-p21 fusion to p21-
depleted cells indicates that a critical period for p21 expression is early S phase since 
PIPCdt1-p21 cells have sufficient p21 in G1. Cells lacking p21 in early S showed both an 
increase in the proportion of cells that failed S phase and a reduced ability to recover from a 
strong replication block. Particularly with respect to the increase in BrdUneg /S phase cells, 
we were initially surprised to observe what appeared to be a mid-to-late S phase phenotype 
since mid-S phase cells have already degraded p21. In addition, the recovery from an HU 
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block seems unrelated to the degradation rates of the p21 fusions during the arrest since 
both are degraded at 0 h. We consider however that these phenotypes are a downstream 
consequence of insufficient p21 in early S phase leading to overall higher levels of 
endogenous damage prior to or during the HU block and a longer recovery time. Even in the 
absence of HU treatment, we observed a small (though not statistically significant) increase 
in -H2AX positive proliferating cells expressing only the prematurely degraded p21 (data 
not shown). The combination of preexisting replication stress with an HU challenge could 
account for the poor recovery from replication arrest. 
 Our findings suggest a model for the need to degrade Cdt1 at the very beginning of 
S phase but delay p21 degradation until later in S phase (Figure 2.16B). In normal cells 
Cdk2 activity begins to rise in late G1 due to the increase in cyclin E, but p21 is still present 
(Figure 2.1). Once S phase begins and PCNA is loaded at early-firing origins, the continued 
presence of p21 restrains S phase progression by slowing the rise of Cdk2 activity.  In this 
model, early S phase cells have lower total Cdk2 activity than mid-S cells but the 
intermediate Cdk2 activity supports some origin firing and PCNA loading. During this early S 
phase period, Cdt1 is rapidly degraded to prevent origin re-licensing and re-replication. This 
rapid degradation may be particularly important because two of the blocks to re-replication, 
the geminin inhibitor protein and cyclin A, are lower in early S phase than when they reach 
maximal levels later in S (Wohlschlegel et al. 2000; Girard et al. 1991; Rosenblatt et al. 
1992). If p21 is degraded prematurely, Cdk2 activity may rise too early leading to more 
origins firing at the beginning of S phase than normally should, and subsequent replication 
stress. In support of that notion, manipulations in both yeast and X. laevis experimental 
systems that shift origin firing towards early S phase induce replication stress markers  
(Woodward et al. 2006; Gibson et al. 2004; Mantiero et al. 2011). Replication fork speed 
may also be affected by p21 tightly bound to PCNA (Waga et al.,1994). The aggregate of  
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Figure 2.16. 
 
Figure 2.16.  Model (A) Despite lower binding affinity for PCNA, the Cdt1 PIP degron 
recruits more Cdt2 than the p21 PIP degron does. (B) The normal relatively delayed 
degradation of p21 by CLR4Cdt2 permits only intermediate Cdk2 activity in early S phase 
rather than maximal activity at S phase onset. The more gradual degradation of p21 
prevents replication stress (see Discussion).   
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effects such as these may explain the higher likelihood of S phase failure in cells that 
prematurely degrade p21. We conclude therefore that some key molecular events at the 
G1/S transition must happen in a defined order to ensure a normal S phase progression. 
These findings raise the possibility that many aspects of cell cycle transitions are also 
programmed to occur in a stereotypical sequence to ensure genome stability. 
Materials and Methods 
Cell culture and manipulations 
HCT116 and HEK 293T cells were obtained from ATCC and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma) supplemented with 10% fetal calf serum 
(Sigma). U2OS TRex cells were a gift from John Aster (Malecki et al. 2006) NHF-hTert cells 
are normal human fibroblasts immortalized with telomerase. HCT116 cells were 
synchronized in prometaphase by treatment with 2 mM thymidine for 18 h followed by 
release into 100 nM nocodazole. To obtain populations of cells in either G1 or early S phase, 
cells were released from the prometaphase arrest by mitotic shake-off, re-plated in complete 
medium, and collected at either 2.5 h (G1) or 4 h (early S phase). To arrest replication forks 
and measure recovery, U2OS cells expressing empty vector, wild-type p21, or PIPCdt1-p21 
were treated with 2 mM hydroxyurea (HU) for 16 h and released into fresh media. UV 
irradiation experiments were performed using a single dose of 20 J/m2 in a Stratalinker 
(Stratagene, La Jolla, CA). Additional DNA damage repair triggers used were 100 µM tert-
butyl peroxide (Sigma) and 10 µg/ml bleocin (EMD Millipore). Lentiviral packaging was 
performed by standard protocols in 293T cells followed by selection with 1 µg/ml puromycin. 
Synthetic duplexed RNA oligonucleotides were synthesized by Life Technologies; 
Luciferase (5’- CUUACGCUGAGUACUUCGA-3’); p21-2 (5’- 
AACAUACUGGCCUGGACUGUU-3’), UBCH8 (5’- GCAAGAACCAGAAAGAGAA-3’) 
UBE2G1 (5’– GGGAAGAUAAGUAUGGUUA-3’) UBE2G2 (5’-
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UGACGAAAGUGGAGCUAAC-3’). Significance testing utilized the two-tailed Student t test 
on at least 3 biological replicates.  
Antibodies  
Antibodies were purchased from the following sources: p21, PCNA, and anti-HA from 
Santa Cruz; PR-Set7 and Cdt1 from Cell Signaling Technologies,  alpha-tubulin, GAPDH, 
and GST from Sigma, anti-BrdU from BD Biosciences, anti-phospho-Histone H2A.X 
(Ser139) from EMD Millipore, anti-HA from Roche Life Sciences, anti-UBCH8 and anti-
UBE2G1 from Protein tech, and anti-UBE2G2 from Thermo Scientific. Antibodies to human 
Cdt1 (Cook et al. 2004) and Cdt2 (Abbas et al. 2008) have been described previously. 
AlexaFluor 488, Rhodamine Red-X, and Cy5 donkey secondary antibodies for 
immunofluorescence microscopy were obtained from Jackson ImmunoResearch 
Laboratories.  
Plasmids and recombinant protein preparation 
For expression in mammalian cells, wild-type (WT) p21, PIPCdt1-p21, PIPCdt1-GST, 
PIPp21-GST, WT Cdt1 bearing an HA epitope tag, Cdt1 15-546-HA (“ΔPIP”) , and PIPp21-
Cdt1-HA alleles were subcloned into pENTR vectors and subsequently transferred into a 
retroviral vector, pQCXIP CMV TO/DEST (Campeau et al. 2009) (Addgene ID: # 17386) or 
to pDESTJC16 or pDESTJC17 by Gateway cloning. K153A mutation in p21 was generated 
through site-directed mutagenesis. Lentiviral PIPmCdt1-p21, PIPCdt1-p21PIPm, PIPp21-p21, 
and PIPm-p21 plasmids were generated by sucloning cDNAs into a pCDH IRES mcherry 
vector (System Biosciences). pBabe-puro-H2B-mCherry was subcloned from PGK-H2B-
mCherry (gift from Mark Mercola, Addgene plasmid # 21217) into pBabe-puro using 
standard methods. pDESTJC16 and 17 are a derivatives of pcDNA5/FRT/TO-Venus-Flag-
Gateway (gift from Jonathon Pines, Addgene plasmid # 40999) in which the hygromycin 
resistance gene has been replaced with either the puromycin orthe nourseothricin 
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resistance genes respectively using standard methods.   pEXP-JC17- Cdt1-mCerulean3-
P2A-Venus-NLS-p21, pEXP-JC17-2HN-Venus, and pEXP-JC17-Venus-NLS-p21 were 
generated by Gateway cloning from pENTR vectors. Both Venus and mCerulean3 
fluorophores were selected for their relative brightness and rapid fluorescence maturation. 
Plasmids for expressing WT and PIPm-p21 glutathione-S-transferase (GST) fusions were 
generated by recombinational Gateway cloning (LR clonase, Invitrogen) between pENTR 
plasmids and pDEST15. Additional plasmids for PIPCdt1-GST and PIPp21-GST fusions were 
constructed by subcloning cDNAs into pET11b vector (Novagen). The PIP mutants were 
generated by site-directed mutagenesis to introduce alanine codons a positions 
corresponding to Cdt1 amino acids 5 through 8 or p21 amino acids 146-150. PIP degron 
fusions carried human Cdt1 amino acids 1-28 or human p21 amino acids 137-164. GST 
fusions were transformed into BL21 (DE3) cells (Invitrogen) and partially purified as 
described previously (Cook et al. 2004).  
Protein lysate preparation 
Whole-cell lysates were prepared either by direct lysis of equal cell numbers in 2X 
Laemmli sample buffer with 10% β-mercaptoethanol or in CSK buffer (Cook et al. 2002) 
supplemented with 0.1% Triton X-100 and protease and phosphatase inhibitors. 
Densitometry analysis of immunoblots of lysates was performed using NIH Image J software 
(normalized to tubulin expression). At least two film exposures were chosen for 
quantifications of each protein analyzed, such that one lane of each exposure was of equal 
band intensity and thereby served as a normalization control. Quantifications represent 
percentages of each protein remaining relative to the starting amount prior to UV irradiation 
(time=0 min). Half-lives were estimated from semi-log plots of the ln (% remaining) vs time.  
GST pull-down assays 
Recombinant GST fusion proteins described above were immobilized on glutathione-
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sepharose 4B resin (GE Healthcare). UV-irradiated HEK293T cells were lysed in CSK buffer 
(supplemented with 0.1% Triton-X-100 plus protease and phosphatase inhibitors). 
Chromatin fractions were prepared as described previously (Cook et al. 2002) and subjected 
to low-power sonication of Triton-insoluble pellets to fragment DNA-bound material. Soluble 
chromatin fractions were clarified by centrifugation at 13,000 x g for 15 min at 4°C and 
incubated with bound GST fusion proteins for 3 h with rotation at 4°C. Beads were washed 
three times in supplemented CSK buffer and bound proteins were eluted by boiling for 5 
minutes in 40 μl 2X SDS sample buffer. 
Immunofluorescence microscopy 
HCT116 cells synchronized in either G1 or early S phase were pulse-labeled with 50 µM 
bromodeoxyuridine (BrdU) for 30 min prior to fixation in 2% paraformaldehyde for 15 
minutes. DNA was denatured with 1.5 N hydrochloric acid for 15 min. Cells were 
permeabilized with 0.5% Triton-X-100 for 5 minutes and then blocked in 0.1% BSA for 1 
hour. Incubations with primary and fluorescent secondary antibodies were performed in 
0.1% BSA for 1 hour at 37°C and washes were for 10 minutes at room temperature. DAPI 
(4',6-diamidino-2-phenylindole) staining (0.1 µg/ml) was performed for 10 minutes, and cells 
were mounted using Prolong Gold Antifade Reagent (Life Technologies/Molecular Probes).  
For indirect immunofluorescence microscopy, images were acquired using Velocity 
Software and a 60X/1.42NA (PlanApo) DIC oil immersion objective mounted on a Olympus 
1X81 inverted microscope equipped with a Hamamatsu Orca ER cooled CCD camera. For 
fluorescence intensity measurements, the average values for integrated nuclear Cdt1 and 
p21 fluorescence from control and experimental cell samples were subjected to background 
subtraction to obtain the specific nuclear fluorescence levels. 
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Flow cytometry analysis 
Cells to be analyzed by flow cytometry were labeled with 10 M BrdU for 1 hour prior to 
trypsinization and fixation in 70% ethanol. Nuclei were stained with anti-BrdU antibody (BD 
Biosciences) followed by AlexaFluor 488-labeled secondary antibody (Jackson 
ImmunoResearch) and counterstained with propidium iodide. Flow cytometry analysis was 
performed using a Cyan FACScan (DakoCytomation) and Summit v4.3 software 
(DakoCytomation). 
Fixed cell imaging analysis 
Asynchronous U2OS cells expressing Cdt1-mCerulean3-P2A-Venus-p21 induced with 
20 ng/ml doxycycline were fixed with 2% paraformaldehyde using standard methods and 
imaged on a Nikon Ti Eclipse inverted microscope running NIS Elements software V4.30.02 
with an Andor ZYLA 4.2 camera using a 20X objective. Images of randomly-selected fields 
were collected in all three channels (CFP, YFP, and RFP) using exposure times producing 
approximately equivalent nuclear fluorescence in the three channels. ImageJ (V1.49p) was 
used to identify nuclei on the H2B-mCherry images using the nucleus counter plug-in from 
the ImageJ Cookbook. Cells were scored for Venus and/or mCerulean3 expression over 
three randomly-selected fields (n>150 per field). 
Live-cell imaging analysis 
Asynchronous U2OS cells stably expressing histone H2B-mCherry and  PIPCdt1-p21-
Venus, or Venus-NLS-p21 were plated on 35 mm glass bottom plates (In Vitro Scientific) in 
imaging media (phenol-red free DMEM (Invitrogen) supplemented with 10% FBS and 1X 
pen/strep) approximately 24 hours before being imaged.  Cells were imaged for a minimum 
of 18 hours using a Nikon Ti Eclipse microscope operated by NIS Elements software 
V4.30.02 with an Andor ZYLA 4.2 camera and a custom stage enclosure to ensure constant 
temperature, humidity, and CO2 levels. Protein expression was induced with 10 ng/ml 
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(PIPCdt1-p21), or 30 ng/ml (Ven-NLS-p21) doxycycline 20 hours before imaging. Fresh media 
with doxycycline was added 5 hours before imaging. Images were flat-field corrected using 
NIS Elements. 50 cells of each line were selected for analysis based on Venus expression 
and visualization of a complete cycle (minimum mitosis to S phase degradation).  
Single-cell fluorescence intensity was quantified using custom MATLAB software, which 
is available upon request. In each frame, the nuclei of individual cells were identified using 
an adaptive threshold followed by watershed segmentation of the H2B-mCherry channel. 
Cells were tracked through consecutive frames by tracking nearest nuclear centroids 
between frames. The resulting nuclear borders were used to quantify average fluorescence 
intensity from other channels (e.g., p21-Venus). Missing time points, which were generally 
no more than 1-2 frames, were interpolated linearly. To compare the decay kinetics of 
individual cells, fluorescence intensity was normalized between 0 and 1. The delay time, 𝑇𝑑, 
was calculated by fitting each trace to an inverse sigmoidal Boltzmann curve, 𝑓(𝑡) =
1
1+exp(
𝑡−𝑡𝑑
𝑡𝑠
)
. 
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CHAPTER 3: IDENTIFICATION OF MECHANISMS CONTRIBUTING TO ORIGEN 
LICENSING INHIBITION DURING CELLULAR QUIESCENCE2 
Introduction 
 In Chapter 1, I discussed the origin licensing reaction, in which origins are rendered 
competent for replication by the chromatin-loading of the MCM helicase.  This licensing 
reaction is highly regulated to ensure that it only occurs during G1 phase and is restricted 
beyond the G1/S transition to prevent DNA re-replication.  As mentioned in Chapter 1, 
restriction of new origin licensing during S and G2 phases is accomplished by a variety of 
overlapping mechanisms, including transcriptional regulation of licensing proteins, Cdc6 
nuclear export, expression of protein inhibitors (e.g. geminin), and ubiquitin-mediated 
proteolysis via SCFSkp2, CRL4Cdt2, and the APC/C E3 ubiquitin ligases (reviewed in (Arias 
and Walter 2007; Blow and Dutta 2005; Sclafani and Holzen 2007; Machida et al. 2005). 
 Another point in the cell cycle in which licensing activity is strictly inhibited is during 
cellular quiescence (G0).  In fact, the absence of chromatin-bound MCMs is a distinguishing 
feature of quiescent cells, as it helps maintain them in their non-proliferative state  
(Malumbres and Barbacid 2001).  How licensing activity is restricted during G0 is still not 
entirely understood, however.  One of the major mechanisms known to limit licensing in 
quiescence is ubiquitin-mediated proteolysis of the licensing factor Cdc6 by APCCdh1, which 
                                                 
2 Results from Chapter 3 are currently unpublished. 
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is highly active in G0 cells (Petersen 2000).  Also, in some cell lines, Cdt1 levels are 
transcriptionally downregulated as cells exit the cell cycle (Xouri et al. 2004; Mailand and 
Diffley 2005).  It was shown previously, however, that reconstitution of Cdc6 expression in 
quiescent REF52 cells cannot overcome the resistance to licensing during cell cycle exit 
(Cook et al. 2002), suggesting the existence of additional mechanisms.  
 In developing hypotheses for additional factors restricting licensing activity during G0 
phase, we considered recent evidence from our lab implicating stress-activated mitogen-
activated protein kinase (MAPK) activity in the regulation of origin licensing.  The stress 
MAPKs p38 and JNK are activated by a variety of environmental and genotoxic stressors 
and play key roles in controlling cell proliferation among other important processes (Wagner 
and Nebreda 2009; Thornton and Rincon 2009) (Figure 3.1A). In the study from our lab, we 
observed that induction of the stress MAPK pathway using acute stressors such as sorbitol 
treatment promotes phosphorylation of the Cdt1 licensing factor; this MAPK-induced 
phosphorylation has two important effects on Cdt1 regulation: (1) It results in increased Cdt1 
stability by preventing Cdt1 binding to Cdt2, abrogating CRL4Cdt2-mediated ubiquitination, 
and (2) it disrupts Cdt1 function in origin licensing.  In this same paper, our lab also 
observed an inverse relationship between stress MAPK levels and the timing of licensing 
onset in G1; In G0 cells, stress MAPK activity is quite high, but these levels drop 
coincidentally with the onset of MCM loading during G1 (Chandrasekaran et al. 2011) 
(Figure 3.1B).  Previous studies also showed that p38 activity is important for establishing 
contact inhibition in response to serum withdrawal (Faust et al. 2005) as well as controlling 
cell cycle exit in primary myoblasts (Perdiguero et al. 2007).  Whether this elevated stress 
MAPK activity in G0 is linked to inhibition of licensing activity is still unclear.     
Based on this collective evidence, we hypothesized that stress MAPK activity 
contributes to licensing inhibition in G0, through direct phosphorylation of Cdt1 or perhaps  
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Figure 3.1. 
 
 
 
Figure 3.1.  Regulation of MCM loading (licensing) and stress MAPK activity during 
the cell cycle. (A) Pathway for activation of the stress MAPKs p38 and JNK upon acute 
cellular stress.  Stress MAPK activity blocks MCM loading (Chandrasekaran et al. 2011). (B) 
(top) MCM loading status during the cell cycle.  Licensing is allowed only in G1, but blocked 
in quiescence and beyond the G1/S transition. Mechanisms contributing to licensing 
inhibition in G0 are the focus of Chapter 3. (bottom) Stress MAPK activity (and Cdt1 
phosphorylation by stress MAPKs) is inversely correlated with MCM loading during the cell 
cycle.  
 
 
 
 
 
? 
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other licensing factors.  In this project, we tested our hypothesis by combining stress MAPK 
inhibition with artificial restoration of the licensing factors Cdc6 and Cdt1 in quiescent T98G 
cells.  While results confirmed previous observations of licensing inhibition, Cdt1 
phosphorylation, and elevated stress MAPK activity in G0 phase, addition of pharmacological 
inhibitors of stress MAPKs had little effect on restoring licensing activity during G0.  
Therefore, we turned our attention to identifying differential regulators of MCM loading in G0 
vs. G1 cells in an unbiased mass spectrometry screen.  Using this approach, we were able 
to identify novel MCM interactions, including some with previously characterized roles in cell 
proliferation control.  Here, I summarize these findings and discuss optimization of the 
original mass spectrometry screen for better detection of MCM regulators contributing to 
quiescence establishment and maintenance.   
Results 
Quiescent cells are resistant to MCM loading despite artificial restoration of licensing factors. 
 To determine whether there are other mechanisms contributing to the inhibition of 
MCM loading during quiescence besides Cdc6 degradation by APCCdh1, we artificially 
restored licensing factors Cdc6 and Cdt1 to quiescent cells.  Serum-starved T98G cells are 
distinguished by the absence of Cdc6 and Cdt1, in agreement with previous observations 
(Mailand and Diffley 2005); levels of Cdc6 and Cdt1 re-accumulate upon cell cycle re-entry 
and progression into late G1, coinciding with the timing of MCM chromatin loading (Figure 
3.2A).  We reconstituted Cdt1 expression in these cells by stable integration of a wild-type 
Cdt1 construct and infection with an adenovirus encoding a stable, APCCdh1-resistant form of 
Cdc6 (“S3D”).  Despite ectopic expression of Cdc6 and Cdt1 to G1 levels, when we 
performed chromatin fractionations to compare relative amounts of chromatin-bound MCMs, 
we found that quiescent cells were still resistant to MCM loading in comparison to G1 cells, 
in agreement with published results (Cook et al. 2002) (Figure 3.2B, compare lanes 2 and  
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Figure 3.2. 
 
 
Figure 3.2.  Quiescent cells are resistant to MCM loading. (A)  T98G cells were serum-
starved for 48 h and then released into complete medium for the indicated times. Cell 
lysates were fractionated to monitor the chromatin association of MCM2 by immunoblotting. 
In parallel, immunoblots were performed on whole cell lysates for total MCM2, Cdt1, and 
Cdc6.  (B)  T98G cells stably expressing Cdt1-WT-V5 were serum-starved (lane 1), released 
from quiescence and collected at 12 h in late G1 (lane 2), or serum-starved and infected 
with either control Ad-GFP adenovirus or Ad-mycCdc6-S3D at various multiplicity of 
infection (MOI) values: (MOI= 10, 25, and 50 ffu/cell for lanes 4,5, and 6 respectively).  
Chromatin fractions (top) and whole cell lysates (bottom) were analyzed by immunoblotting 
for the indicated proteins.  
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6). Thus, we concluded that there are other mechanisms besides the absence of licensing 
factors to account for MCM loading inhibition in G0. 
Stress MAPK inhibition is not sufficient to restore MCM loading to quiescent cells. 
 As mentioned in the Introduction, we speculated that high stress MAPK levels in G0 
cells could be a contributing factor to MCM loading inhibition, given our previous observation 
that sorbitol-induced MAPK activation was sufficient to block licensing activity 
(Chandrasekaran et al. 2011).  Indeed, we did observe evidence for upregulated stress 
MAPK in G0 cells, in line with published findings.  For instance, we performed a time-course 
experiment to monitor MCM loading and phospho-p38 levels in T98G cells following release 
from quiescence into G1 phase, and saw that these markers were inversely correlated; 
phopho-p38 levels, indicative of p38 activation, were elevated in G0 cells and decreased in 
late G1 cells, coinciding with the onset of MCM loading (Figure 3.3A). Furthermore, 
phosphorylation of a downstream target of p38, MAPKAP-K2, was high in G0 arrested cells 
and low in G1. (Figure 3.3B).  Interestingly, we also observed that Cdt1 was predominately 
in its phosphorylated, licensing-deficient, form in G0 cells as evidenced by its reduced 
electrophoretic mobility, and that Cdt1 de-phosphorylation occurred in late G1 (Figure 
3.3B).  Based on this evidence, we hypothesized that stress MAPK inhibition, either through 
the use of pharmacological inhibitors or siRNAs targeting p38 and JNK, would overcome the 
restriction to licensing in G0 by reducing the inhibitory phosphorylation of Cdt1 and perhaps 
other licensing factors. When we reconstituted Cdc6 and Cdt1 expression in quiescent cells 
and treated them with pharmacological inhibitors for p38 and JNK, we did not observe a 
rescue in licensing activity to G1 levels, however (Figure 3.3C, lanes 2 and 6).  In the same 
experiment, inhibition of p38 and JNK isoforms with siRNAs produced similar results (data 
not shown).  These results encouraged us to investigate other potential mechanisms for 
licensing inhibition during G0. 
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Figure 3.3. 
 
Figure 3.3.  Inhibition of elevated stress MAPK activity in G0 cells is insufficient to 
restore licensing activity. (A) T98G cells were rendered quiescent and re-stimulated for 
the indicated times with medium containing 10% FBS.  Chromatin fractions (top) and whole 
cell lysates (bottom) were prepared and analyzed by immunoblot for the indicated proteins.  
(B)  T98G cells were either rendered quiescent (G0) or re-stimulated and harvested in late 
G1 (12 h post-serum).  Lysates were analyzed for p-MAPKAP-K2 and Cdt1 levels by 
immunoblot.  (C)  T98G cells with stably integrated Cdt1-WT-V5 were serum-starved or re-
stimulated to enter late G1 (indicated by - and + serum, respectively) and infected with 
adenoviral constructs and treated with MAPK inhibitors as indicated.  Cells were infected 
with an MOI=25 of either control Ad-GFP or Ad-myc-Cdc6 adenoviruses for 24 h prior to 
harvesting.  MAPK inhibitor treatments were performed for 4 h prior to harvesting with 
inhibitors targeting both p38 and JNK (see Methods). 
73                                                                                                                                     
MS/MS analysis of protein interactions with G0 vs. G1 MCM complexes 
 In developing alternative hypotheses, we considered the possibility that MCM-
interacting proteins could be contributing to the dynamic regulation of origin licensing in G0 
vs. G1 in two different ways: (1) Protein factors may preferentially bind MCMs in G0 to block 
helicase-loading, or (2) MCM-interacting proteins may promote helicase-loading only in 
proliferating cells (Figure 3.4A). These possibilities are not mutually exclusive.  Therefore, 
to identify differential MCM interactions fitting into these two categories, we performed an 
unbiased mass spectrometry screen in collaboration with Ben Major’s lab.  We synchronized 
T98G cells in either G0 or G1 as described in Methods, prepared lysates, and performed 
large-scale immunoprecipiations (IPs) of MCM complexes from each set of lysates using an 
antibody against endogenous MCM2.  Large-scale anti-MCM2 IPs were performed in 
triplicate along with negative control samples for each condition (lysates incubated with 
beads but no antibody) and subjected to on-bead trypsin digestion and filter-aided sample 
preparation (FASP) clean-up before liquid chromatography and MS/MS analysis (according 
to Major Lab protocols).  
 Prior to mass spectrometry, we verified the efficiency of each IP by using a small 
amount (10%) in immunoblot analyses for MCM subunits (Figure 3.4B).  We also checked 
that cells were properly synchronized by monitoring Cdc6 and Cdt1 levels by immunoblot 
(Figure 3.4C) and by performing flow cytometry analysis of DNA synthesis (BrdU 
incorporation) vs. DNA content (PI staining) (Figure 3.4D).  Cdc6 and Cdt1 levels were low 
in G0 cells, and the majority of cells (90.0%) had a 2C DNA content and did not incorporate 
BrdU, indicating that these cells were synchronized appropriately.  We did note that while 
most cells in our G1 sample (12 h post-serum) did not incorporate BrdU during the labeling 
period (68.6%), a percentage showed evidence of BrdU incorporation to indicate early S 
phase entry (25.1%).  However, Cdt1 levels were still very high in G1-synchronized samples 
(Figure 3.4C) indicating that most of the cells had not yet entered S phase.  In the  
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Figure 3.4. 
 
 
Figure 3.4.  Verification of G0 and G1 synchronizations and MCM purification strategy prior to 
MS/MS analysis. (A) Hypothesis for MCM complex regulation in G0 vs. G1 cells.  Either an inhibitor 
molecule preferentially binds MCM complexes in G0 cells that is absent/inactive during G1, or an 
activator molecule enhances licensing activity exclusively in G1 cells but not G0 cells.  (B) T98G cells 
were synchronized in either G0 or late G1 (12 h post serum re-stimulation).  Lysates were used in CO-
IPs with or without an antibody against endogenous MCM2, as indicated.  Purification of MCM 
complexes was verified using 10% of each CO-IP sample in immunoblot analysis with a pan-MCM 
antibody. Remaining sample was used as one replicate for our LC-MS/MS analysis (C)  Whole cell 
lysates from cells synchronized as in (B) were analyzed by immunoblot for Cdt1 and Cdc6 levels. (D)  
T98G cells were synchronized in G0 and released into complete medium containing serum for the 
indicated times. Cells were labeled for 1 h with BrdU prior to fixation and analyzed by flow cytometry 
with anti-BrdU antibody to detect DNA synthesis (y-axis) and with propidium iodide for DNA content 
(x-axis). 
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future, a slightly earlier time-point (10-11 h) should be collected to ensure that late G1 
samples are void of any early S phase cells that could skew results. 
 As expected, resulting MS/MS datasets confirmed the presence of all six subunits 
forming the MCM2-7 heterohexamer with high sequence coverage (>50%) in both the G0 
and G1 anti-MCM2 IP samples, but not in the respective control samples (Table 3.1). While 
many novel MCM-interactions were identified in both the G0 and G1 conditions, there were 
few associated proteins identified which bound exclusively in G0 or G1 lysates. A subset of 
proteins fitting into each of these categories is shown in Table 3.2.  We further prioritized 
our list of MCM interactions based on variety of different factors such as the SAINT 
algorithm (a bioinformatics tool that assigns confidence values to protein-protein interaction 
data) (Choi et al. 2011), relative abundance in IP samples (normalized spectral abundance 
factors (NSAF) values) (Paoletti et al. 2006), Gene Ontology (GO) term analysis, known 
involvement in cell cycle regulation, etc.  Based on this analysis, we generated a list of high-
priority candidates for further follow-up experiments (Table 3.3).  The full dataset is 
uploaded as a supplemental file to this dissertation. 
Validation of prioritized MCM interactions 
 Our first goal was to validate our list of MCM interactions by co-immunoprecipitation 
and immunoblot analysis.  To facilitate these experiments, we obtained cloned open reading 
frames (ORFs) of candidate genes from the Human ORFeome collection v5.1, and 
generated Flag-tagged expression constructs using Gateway cloning with a custom lentiviral 
vector (pHAGE-CMV-FLAG-DEST, gift from Ben Major).  We also obtained cloned cDNAs 
for mammalian expression from other sources.  We transiently transfected HEK293T cells 
with expression vectors for 24 h and immunoprecipitated MCM complexes using an MCM2 
antibody.  We then detected co-immunoprecipitated target proteins using an antibody 
against the N-terminal FLAG tag in each construct.  Using this approach and with the help of 
76                                                                                                                                     
a rotation student at the time, Jacob Matson, we were able to validate at least 8 interactions 
from our list (see Table 3.3).  We also used these vectors to generate stable cell lines in 
T98G cells for validation.  Figure 3.5 shows examples of validated MCM interactions using 
this approach. 
 
Table 3.1.  Detection of MCM subunits in MS/MS IP samples 
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Table 3.2. Examples of novel constitutive, G0-induced, and G1-induced MCM 
interactions. 
 
Constitutive interactions 
 
 
G0-induced interactions 
 
 
Uniprot ID Gene Namedescription siRNA phenotypes partners of note Avg Saint Max Saint
P51610 HCFC1 VP16, regulation of INK locusIncreased cell number in G1, small nuclei in G1tra scription factors 0.60 0.97
Q86UU1 PHLDB1 pleckstrin homology-like domainDecreased nuclei size in G2M sh3kbp1 (only one partner) 0.7077 0.986
P19474 TRIM21
E3 Sjogren syndrome 
antigen A1
dec influenza rep'n Synthetic lethal 
with Ras Cul1-Skp2, fadd, interferon regulatory f30.9998 1
Q9UBP0 SPAST spastin Increased G1 DNA content, synth let with Ras, Wnt signaling up partners in protein sorting, stress tolerance?0.6102 0.935
O43150 ASAP2 Arf-GAP fak2 0.8093 0.987
P14136 GFAP glial fibrillary acidic protein Increased circadian period length transcription factors, f box protein 0.1473 0.884
Q07666 KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1cell divisio , ciliogenesis, HR pi3K, prmt1, src, chromatin remodelers0.7173 0.999
Q13425 SNTB2 Beta-2-syntrophin ciliogenesis mark2, dystrophin 0.6373 0.951
P51610 HCFC1 VP16 ncreased cell number in G1, small nuclei in G1transcription factors 0.6003 0.967
Q96B97-2 SH3KBP1
SH3 domain-
containing kinase-
binding protein 1 cell division, ciliogenesis 0.5495 0.929
Q9Y5B9 SUPT16H
chromatin-specific 
transcription 
elongation factor 
140 kDa subunit cell division, ciliogenesis, TONSL, MCM4, SSRP1, BRCA1, TIPIN, 0.5355 0.949
Q9Y294 ASF1A
Histone chaperone 
ASF1A cell division, synthetic lethal with MLN4924MCM subunits, RIF1, 0.378 0.773
Q13263-2 TRIM28
Transcription 
intermediary factor 1-
beta cell division, cell viability, ciliogenesis cul1, cul3, CDK2, E2Fs 0.3257 0.8
P49815-2 TSC2 Tuberin cell division, ciliogenesis 0.3012 0.831
Q6SZW1-2 SARM1 sterile alpha and TIR motif containing 1cell division, genome stability 0.2985 0.899
SCLY selenocysteine lyase cell division, ciliogenesis 0.2832 0.865
Uniprot ID Gene Namedescription siRNA phenotypes partners of note Avg Saint Max Saint
P46939 UTRN dystrophin-related protein 1 cell division, ciliogenesis, HR mark2 kinase (cytoskeleton) 0.8333 1
Q8WXX5 DNAJC9
DnaJ (Hsp40) homolog, 
subfamily C, member 9 cell growth and viability (fly) cul1 cul3 0.1203 0.722
Q3V6T2 CCDC88A G{alpha}-interacting vesicle-associated protein/Akt phosphorylation enhancernone signifi ant bard1, smad, AKT 0.157 0.942
P57721 PCBP3 poly(rC) binding protein 3 HepC replication blocked transcription factors, RNA BP 0.2885 0.768
P15531 NME1 NM23 nucleoside diphosphate kinase 1cell rolif ration, HepC replication aurorak, rora 0.3227 0.737
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G1-induced interactions 
 
Table 3.3.  List of prioritized hits from MS/MS screen for validation experiments 
 
 
Uniprot ID Gene Namedescription siRNA phenotypes partners of note Avg Saint Max Saint
P47756 CAPZB F-actin capping protein some nuclear parnters (p53, ER, brca1) 0.5667 0.943
Q9Y4B5 SOGA2
coiled-coil domain-
containing protein 165 no hits ATM/ATR substrate, Mark2 and 4 0.4667 0.785
Q9BXF6 RAB11FIP5
Rab effector protein, vesicle 
trafficing protein Increased gamma-H2AX phosphorylation 0.4015 0.849
Q96HA7-2 TONSL Tonsoku-like protein cell division, cell cycle regulation, ASF1a, MCM subunits, SUPT16H, BRCA10.3858 0.751
Q9UQF2 MAPK8IP1
JNK MAP kinase 
scaffold 1 cell division, cell proliferation JNK, c-jun, 0.3568 0.939
P15531 NME1 cell proliferation, HepC replication aurorak, rora 0.3227 0.737
Gene ID Gene Name source of vector expression vector (Midi-prep)validated by CO-IP?
9479 MAPK8IP1 K. Verhey pcDNA 3 Flag no
6737 TRIM21 ORFeome library Flag-nterm (Major) yes
4659 PPP1R12A ORFeome library Flag-nterm (Major) no
51540 SCLY ORFeome library Flag-nterm (Major) yes
90957 DHX57 ORFeome library Flag-nterm (Major) no
10657 KHDRBS1 (Sam68) Addgene pcDNA3 HA N-term yes
3054 HCFC1 ORFeome library Flag-nterm (Major) yes
30011 SH3KBP1 ORFeome library Flag-nterm (Major) yes
11198 SUPT16H Jurgen Marteijn GFP HA PLHLX published
4796 NFKBIL2 (TONSL) ORFeome library Flag-nterm (Major) yes
25842 ASF1A ORFeome library Flag-nterm (Major) published
3191 HNRNP1
10155 TRIM28 Addgene pKH3-HA no
23098 SARM1
7249 TSC2 ORFeome library not cloned yet
23234 DNAJC9
5905 RANGAP1 ORFeome library Flag-nterm (Major) yes
26056 RAB11FIP5
6749 SSRP1 Jurgen Marteijn GFP clonech (N and C-term)published
9782 MATR3 ORFeome library N-term FLAG
57488 ESYT2 ORFeome library not cloned yet
23255 KIAA0802 (SOGA2) ORFeome library not cloned yet
4830 NME1 ORFeome library Flag-nterm (Major) yes
832 CAPZB ORFeome library Flag-nterm (Major)
23187 PHLDB1 ORFeome library Flag-nterm (Major) no
8853 ASAP2 ORFeome library not cloned yet
2670 GFAP ORFeome library Flag-nterm (Major)
7248 TSC1 ORFeome library not cloned yet
7402 UTRN TOO BIG!
55704 CCDC88A
54039 PCBP3
6683 SPAST
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Figure 3.5. 
 
 
 
 
Figure 3.5. Validation of MS/MS interactions.  Candidate genes were cloned into a 
custom Gateway lentiviral vector (pHAGE-CMV-FLAG-DEST), and resulting vectors were 
then transfected into HEK293T cells for expression of Flag-tagged proteins of interest.  
Lysates were prepared 24 h following transfection and used as input in Co-IPs with or 
without MCM2 antibody.  Interactions with MCM complexes were verified by immunoblot 
analysis of Co-IP samples with an antibody against the N-terminal Flag tag in each 
expression construct.  Shown are two examples of validated interactions with TRIM21 and 
SCLY. 
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Discussion  
 Here, we show that inhibition of MCM loading in quiescence requires additional 
mechanisms other than APCCdh1-mediated proteolysis of Cdc6.  This conclusion was based 
on our observation that forced expression of both Cdc6 and Cdt1 in quiescent T98G cells, 
even above normal G1 levels, was insufficient to fully restore licensing activity.  Therefore, 
we sought to define additional mechanisms explaining the inherent resistance of quiescent 
cells to origin licensing.  In pursuing our original hypothesis that high stress MAPK activity 
may be involved in this licensing block, we showed that pharmacological inhibition of the 
stress MAPKs p38 and JNK was also insufficient to overcome MCM loading inhibition in G0.  
Thus, either stress MAPK activity may be completely unrelated to licensing control in these 
conditions, or it may be involved in combination with other redundant mechanisms and 
signaling pathways.  Additional pharmacological screening (with or without inhibition of 
stress MAPKs) may provide insight into other pathways that could potentially be important to 
establishing unlicensed chromatin in G0. 
 Therefore, we developed an alternative hypothesis that differential MCM interactions 
in G0 and G1 cells could impact MCM loading status.  We were successful in developing a 
system to test this hypothesis through LC-MS/MS analysis of MCM binding proteins from G0 
vs. G1 cellular extracts.  As evidence that MCM complexes were purified successfully for 
analysis, we were able to detect all six subunits of the MCM2-7 heterohexamer with high 
sequence coverage.  We were also able to confirm some published MCM interactions in our 
screen, including ASF1a, SUPT16H, TONSL, MMS22L, and SSRP1 (O’Connell et al. 2010; 
Groth et al. 2007).  On the other hand, we also failed to detect other known MCM binding 
proteins in our G1 sample, including Cdt1 (Cook et al. 2004), Cdc6 (Shin et al. 2003), the 
histone acetyltransferase HBO1 (Burke et al. 2001), ORC subunits (Bell and Dutta 2002)  
and Keap1 (much to the dismay of the Major lab!).  We acknowledge that our 
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synchronization was imperfect, as a percentage of cells had started to enter early S phase 
at the time of collection (25%).  In future attempts, we should collect a slightly earlier time-
point (~10-11 hr post serum re-stimulation), to ensure a true late G1 population and 
enhance our abilities to detect MCM interactions known to occur at this point in the cell 
cycle. 
 Nevertheless, we did successfully uncover some novel MCM interactions which were 
validated by co-immunoprecipitation and immunoblotting.  For instance, one of these 
interactions was with Sam68 (KHDRBS1), which was never shown previously. Sam68 is a 
nuclear RNA binding protein associated with various processes in mRNA metabolism 
(Chawla et al. 2009). A natural isoform of this protein (Sam68∆KH) is expressed specifically 
in quiescent cells, and transfected Sam68∆KH inhibits serum-induced DNA synthesis, which 
is overcome by Sam68 expression.  Thus, Sam68 is proposed to control G1/S progression 
(Maurier 1997). Whether the Sam68∆KH isoform preferentially interacts with MCM 
complexes from quiescent cells to inhibit MCM loading will be an interesting topic for future 
interrogation. 
Another interesting MCM binding protein identified was Nme1 (NM23-H1), which we 
also observed was a G0-induced MCM interaction. The traditionally described role for Nme1 
is to synthesize nucleoside triphosphates other than ATP; however, increased evidence has 
shown alterative roles for this protein in other processes, including differentiation, 
proliferation, and development (Choudhuri et al. 2010). Microarray analysis comparing the 
expression profiles of BJAB (B-cell line) cells transfected with an expression construct for 
NM23-H1 or vector only revealed significant changes in genes involved in cell cycle control, 
apoptosis, and p53 activities.  For instance, NM23-H1 expression caused reduced 
expression of cyclins and CKIs and reduced cell growth, implicating NM23-H1 in the control 
of cell proliferation (Choudhuri et al. 2010). Whether NM23-H1 is differentially regulated in 
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quiescent cells to affect the expression of these proliferative genes is not yet clear, and is 
something we are interested in following up on.  
Finally, an additional protein identified from our screen was Host Cell Factor 1 
(HCFC1), which was previously shown to be involved in cell cycle control and plays several 
roles in transcriptional regulation by tethering the chromatin modifying enzyme Set1/Ash2 
and Sin3 histone deacetylase (HDAC) complexes together. Interestingly, a 50-kDa N-
terminal fragment of HCFC1, arising from proteolysis of the full-length protein, was identified 
only from whole cell lysates of peripheral blood mononucleocytes (PBMCs) and primary 
fibroblasts which were arrested in G0 (Scarr et al. 2000).  It would be interesting to 
determine whether this truncated fragment also influences MCM loading status in quiescent 
cells in follow up experiments. 
 Among these previously uncharacterized MCM interactions were also some that we 
deemed unlikely to occur under physiological conditions.  These include proteins like 
TRIM21 and RANGAP1, which are primarily localized to the cytoplasm in interphase, among 
other likely contaminants such as cytoskeletal proteins, ribosomal proteins, heatshock 
proteins, and elongation factors.  These contaminant proteins are to be expected in any 
mass spectrometry experiment (Mellacheruvu et al. 2013), but we should prioritize 
optimizing our screening method to reduce the number of these false positives and enhance 
our detection of weaker affinity/transient interactions. One potential improvement a current 
graduate student is already employing involves proximity-dependent labeling of proteins 
neighboring the MCM complex by fusing MCM subunits to the promiscuous biotin ligase 
BirA*.  Upon addition of biotin to cultured cells, the BirA* fusion will only biotinylate proteins 
within a 10nm radius; the biotinylated proteins can then be isolated from lysates by affinity 
purification over streptavidin resin (Roux et al. 2012).  In this way, we may be able to 
maximize the number of bona fide interactions occurring during the biotin labeling period, 
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and reduce the number that occur as post-lysis artifacts.  As further improvement to our 
original screen, nuclear fractionation of lysates prior to purification of MCM complexes may 
also help eliminate unlikely cytoplasmic interactions.  We hope that with these 
improvements, we will be able to further characterize proteins that preferentially bind to 
MCMs in either G0 or G1 (see Chapter 4). 
Materials and Methods 
Cell culture and manipulations 
T98G glioblastoma cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum (Sigma).  To synchronize cells in quiescence, 
serum was removed from confluent cells for 48 h; cells were re-stimulated to enter G1 phase 
by re-plating at a 1:3 ratio into fresh medium containing 10% serum.  Cdc6 levels were 
restored to quiescent cells by infecting cells with Ad-mycCdc6-S3D adenovirus 24 h prior to 
harvesting.  MAPK inhibitors (Sigma) were added at the following concentrations for 4 h 
prior to collection: p38 inhibitor SB203580 at 30 M and c-Jun N-terminal kinase (JNK) 
inhibitor SP600125 at 100 M.  
Antibodies 
Antibodies were purchased from the following sources: lamin A/C, Cdc6 (180.2), and 
PCNA (F-2) from Santa Cruz Biotechnologies; phospho-p38 and phospho-MAPKAP-K2 from 
Cell Signaling Technologies; anti-FLAG from Sigma, MCM2 from Bethyl Labs; BrdU and 
MCM2 (BM28) from BD Biosciences; and HRP or Dylight 488 secondary antibodies from 
Jackson Labs.  Antibody against Cdt1 was described previously (Cook et al. 2004). Pan-
MCM antibody was a gift from D. MacAlpine (Duke University). 
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Plasmids and recombinant protein preparation 
Wild-type Cdt1 and Cdt1 5A alleles bearing a V5 tag (not in frame!) were sub-cloned 
into vector pCLXSN for retroviral packaging.  For mass spec validation experiments, 
pDONR223 vectors containing candidate genes were obtained from the Human ORFeome 
collection v.5.1; expression plasmids were generated by Gateway cloning into a pDEST 
Phage N-terminal Flag vector (gift from Ben Major).  Retroviral and lentiviral packaging and 
infection were performed using standard methods.  Stable cell lines were selected using 500 
ng/ml G418  (for pCLXSN vector) and 1 g/ml puromycin (for N-terminal Flag vector). Ad-
GFP and Ad-mycCdc6-S3D adenoviruses were prepared as described previously (Cook et 
al. 2002).  
Protein lysate preparation 
 Protein lysates were prepared by re-suspending cells in CSK buffer (Cook et al. 
2002) supplemented with 0.1% Triton-X-100 and protease and phosphatase inhibitors.  
Chromatin fractions were isolated as described previously by the addition of micrococcal 
nuclease and CaCl2 to Triton-insoluble pellets to release chromatin-bound proteins (Cook et 
al. 2002). 
Large-scale MCM2 immunoprecipitation for LC-MS/MS analysis 
 Four 15 cm dishes of T98G cells were either rendered quiescent according to the 
protocol above (G0 sample) or re-stimulated from quiescence with media containing 10% 
FBS for 12 h (G1 sample).  Cells were harvested and lysed in co-IP #3 buffer (50 mM 
HEPES pH=7.2, 33 mM KAc, 0.5 mM EDTA, 0.5 mM EGTA, 0.1% Triton-X-100 and 10% 
glycerol with protease and phosphatase inhibitors).  Cells were lysed on ice for 20 minutes 
with gentle sonication to release chromatin-bound proteins.  Lysates were divided in half 
and incubated for 1 h with either 5 ug anti-MCM2 antibody (Bethyl Labs) or without antibody 
(negative control sample) with rotation at 4°C.  Lysates were then added to 20 l protein A 
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agarose beads (Roche Life Sciences) and incubated for another 2 h at 4°C; beads were 
washed three times with co-IP #3 buffer and stored at -80°C prior to mass spectrometry 
analysis (10% was retained for immunoblot analysis).  Samples were processed for LC-
MS/MS according to Major Lab protocols. 
Flow cytometry analysis 
Cells to be analyzed by flow cytometry were labeled with 10 M BrdU for 1 hour prior 
to trypsinization and fixation in 70% ethanol. Nuclei were stained with anti-BrdU antibody 
(BD Biosciences) followed by AlexaFluor 488-labeled secondary antibody (Jackson 
ImmunoResearch) and counterstained with propidium iodide. Flow cytometry analysis was 
performed using a Cyan FACScan (DakoCytomation) and Summit v4.3 software 
(DakoCytomation). 
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CHAPTER 4:  CONCLUSIONS AND FUTURE DIRECTIONS 
 We have clearly shown from our studies in Chapter 2 that CRL4Cdt2 substrates are 
degraded sequentially during the G1/S transition and during DNA repair synthesis.  
Furthermore, we demonstrated that these differences in targeting are related to PIP degron 
sequences within substrates.  In our comparison of Cdt1 vs. p21, we found that their 
respective PIP degron sequences confer differences in binding to PCNA/Cdt2 to explain the 
very different destruction rates of these two substrates.  Finally, we concluded that delayed 
p21 degradation is critical for proper replication progression in S phase, as premature p21 
degradation promotes increased replication stress and DNA damage.  These results 
demonstrate the importance of ordered protein destruction for proper coordination of S 
phase replication, and further suggest that substrate ordering may occur via different E3s 
involved at other cell cycle transitions to control key events. 
 This work has several implications in future studies of cell cycle transitions.  While 
many past studies have identified molecular events occurring at these transitions, very few 
have characterized relationships among these events and their importance to cell cycle 
progression, like we have described here for Cdt1 vs. p21 degradation patterns. Based on 
these findings, we conclude that the four-stage model of the cell cycle introduced in Chapter 
1 may be too simplistic; “sub-phases” may exist between cell cycle phases to help anticipate 
the next cell cycle phase, and to ensure that cell cycle progression occurs appropriately.  
From these studies, we have also developed tools to manipulate these inter-molecular 
relationships and assess the consequences on replication progression.  Using our novel 
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live-cell imagining approach, we have further defined degradation patterns of CRL4Cdt2 
substrates on a much more detailed time-scale than would be accomplished using 
conventional biochemical methods.  Going forward, this work will hopefully inspire future 
studies from our lab and others toward developing a more refined kinetic map of cell cycle 
events, allowing others to explore new molecular relationships and to more accurately test 
treatments specific to a given phase.    
 Despite these accomplishments, there are still several outstanding questions from 
this project that will require more work to resolve.  These are highlighted below: 
Future Directions for Chapter 2 
Which specific amino acid residue(s) contribute to differential recruitment of 
PCNA/Cdt2 by PIP degrons? 
 
 Although we confirmed that the PIP degron sequences ultimately determined the 
degradation rates of CRL4Cdt2 substrates, we did not pinpoint which specific degron residues 
accounted for these differences in targeting.  As shown in the alignment in Figure 1.4, 
although the “TD” and “B+4” residues are conserved between all substrates examined in this 
study, there are some variations in a few key degron residues that may confer differences in 
binding to either PCNA or Cdt2 (or both).  There is a phenylalanine residue within the PIP 
box of Cdt1 (QRRVTDFF) that differs from the tyrosine residue at that same position within 
both PR-Set7 and p21.  Also, PR-Set7 and p21 contain a basic patch of amino acids 
upstream of the PIP box that is not found in Cdt1.  Further mutational analyses will be 
needed to interrogate whether any of these different residues (or combinations of residues), 
accounts for the different rates of CRL4Cdt2-mediated proteolysis.  I did create an additional 
allele of p21 in which its native PIP degron sequence was converted to match the sequence 
of the Cdt1 PIP degron.  Oddly, when I performed a UV chase experiment to measure its 
degradation kinetics, I saw that it was not degraded at all (similar to ∆PIP).  Thus, sequence 
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context of PIP degron sequences may also be important for their proper recognition.  
Ultimately, our goal will be to deduce the minimal destruction motif necessary to confer 
“Cdt1-like” or “p21-like” degradation kinetics. 
Are there additional mechanisms to explain the different substrate degradation rates?   
 
 We discovered that the Cdt1 PIP degron binds Cdt2 more efficiently than the 
corresponding p21 sequence, providing one mechanism for its accelerated degradation via 
the same E3 ligase complex.  However, this is probably not the only explanation for why 
these degron sequences are targeted differently.  For instance, we have considered the 
possibility that some substrates of CRL4Cdt2 could be more processive than others, leading 
to preferential multiubiquitination and earlier degradation.  More processive substrates 
would obtain polyubiquitin chains in a single CRL4Cdt2 binding event, whereas distributive 
substrates would require multiple rounds of binding.  In fact, differences in the processivity 
of ubiquitination were observed between substrates of the APC/C during the mitosis/G1 
transition, which also accounts for their ordered degradation (Rape et al. 2006).  Therefore, 
it is conceivable that Cdt1 may be more processive and prone to earlier ubiquitination than 
p21; in vitro and in vivo ubiquitination assays with purified proteins may be helpful in further 
understanding the timing and extent of ubiquitination of different CRL4Cdt2 substrates. 
 CRL4Cdt2 substrate degradation timing may also be influenced by PTMs or 
preferential binding to other proteins.  As an example, we have shown that stress MAPK 
phosphorylation of Cdt1 at the C-terminus blocks the association of Cdt2 with the N-terminal 
PIP degron, resulting in Cdt1 stabilization (Chandrasekaran et al. 2011).  Stress MAPK 
phosphorylation of p21 has also been reported to affect its stabilization (Kim et al. 2002).  I 
have already observed that inhibition of stress MAPK phosphorylation had no appreciable 
effect on the rates of Cdt1 and p21 destruction by CRL4Cdt2 following UV irradiation 
(unpublished observations). There could potentially be other kinase signaling pathways 
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intersecting with CRL4Cdt2 targeting that we are currently unaware of.  In Chapter 2, I also 
saw that abrogation of p21 binding to the protein TRIM39 did not affect its degradation 
pattern, but there could also be other undiscovered p21 binding partners that delay its 
replication-coupled destruction. 
 Finally, other processes downstream of the ubiquitination event may influence the 
timing of proteasomal degradation.  As mentioned in the Introduction, the p97 enzyme was 
recently shown to be important for stripping ubiquitinated substrates from chromatin before 
their delivery to the 26S proteasome.  Perhaps there could be differences in the timing or 
efficiency with which p97 acts on different CRL4Cdt2 targets.  Bolstering this hypothesis, our 
in vitro binding assay shows that p21 binds PCNA more efficiently than Cdt1 does; the 
PCNA-p21 interaction could in fact be too tight to allow for efficient p97-mediated removal of 
ubiquitinated p21 from chromatin, contributing to delayed p21 destruction.  Future work 
needs to be done to test this idea, although we briefly started pilot experiments to test 
sensitivity of substrates to the p97 inhibitor NMS-873 (SelleckChem). 
How is Cdk activity correlated with the rate of p21 destruction by CRL4Cdt2? 
 
 Here, we showed that premature p21 degradation in asynchronously proliferating 
cells causes replication defects during S phase.   To further investigate how early p21 
degradation influences S phase progression, synchronization experiments should also be 
performed to measure BrdU incorporation at the G1/S transition in cells complemented with 
either WT-p21 or PIPCdt1-p21 alleles.  We predict that in agreement with our model, 
accelerated p21 degradation will result in high CDK activity in early S phase, leading to 
premature origin firing and replication stress.  While we speculate that delayed p21 
degradation controls the timing of CDK activation, we did not actually provide evidence for 
this correlation.  Future studies should be focused on determining how p21 destruction rates 
coincide with CDK activity at time-points corresponding to the G1/S transition, using either 
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histone H1 kinase assays or some other readout for CDK2 activity (Cdc6 export from the 
nucleus, for example).  In addition, p21 levels in early S phase could play a role in 
modulating replication fork speed, as the p21 interaction with PCNA was shown to inhibit 
fork progression (Waga S, Hannon GJ 1994).  DNA fiber combing assays or thymidine 
incorporation assays may reveal these differences in replication rates in cells complemented 
with either WT-p21 or PIPCdt1-p21 alleles.  
Does premature p21 degradation promote re-replication? 
 According to our model, we predict that if p21 is degraded prematurely, this could 
present a situation in which CDK levels rise too soon at the G1/S transition when other 
licensing factors are still present (like Cdt1), which could promote the occurrence of re-
licensing and re-replication.  In our flow-cytometry analysis, we did not detect an appreciable 
difference in the percentages of re-replicating cells in cells with prematurely degraded p21, 
however.  A re-replication phenotype may be more readily detected by co-depletion of 
additional factors that normally restrain re-replication in proliferating cells, such as the Cdt1 
inhibitor geminin.  Also, fiber combing assays may be more ideal than flow cytometry 
analysis for showing re-replication events that occur only in early S phase.  It is possible that 
these cells do not progress far enough to show >4C DNA content by flow cytometry analysis 
owing to checkpoint arrests. 
Does ordered substrate re-accumulation by CRL4Cdt2 occur at the end of S phase?  
Why? 
 
 While we have clearly shown that substrate ordering occurs at the G1/S transition, 
we have yet to test whether CRL4Cdt2 targets also re-accumulate in a defined order.  Future 
live-cell imaging analysis of fluorescently-tagged Cdt1 and p21 fusion proteins will focus on 
capturing the S/G2 transition to further discern substrate re-accumulation patterns.  If 
ordered re-accumulation does occur in live cells, we will then investigate the consequences 
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of manipulating this order using cell lines and reagents generated in the course of this study.  
Considering our results from Chapter 2, we also consider it likely that the order of substrate 
re-accumulation is determined by PIP degron sequences, and similar PIP swap experiments 
should be designed to test this possibility. 
What are the relative contributions of SCFskp2 and CRL4Cdt2 to S-phase proteolysis? 
 In the Introduction, I mentioned that several substrates of CRL4Cdt2 are also targeted 
by another S-phase specific E3 ubiquitin ligase, SCFSkp2, including p21, PR-Set7, and Cdt1.  
The relative contribution of these E3 ligases to S phase proteolysis is not yet understood, 
however.  Current evidence suggests that these two pathways are not entirely redundant.  
For example, Skp2 knockout mice are viable, but still exhibit a variety of defects, including 
enlarged nuclei, polyploidy, reduced growth rate, and apoptosis (Nakayama et al. 2000).  On 
the other hand, targeted Cdt2 gene deletion in mice results in early embryonic lethality (Liu 
et al. 2007), and acute depletion of Cdt2 results in massive re-replication that is not affected 
by co-depletion of Skp2 (Kim et al. 2008).  We hypothesize that SCFSkp2 may play a more 
important role later in S phase than CRL4Cdt2; the rationale here is that SCFSkp2 targeting 
requires CDK2-mediated phosphorylation of substrates, and prior degradation of p21 via 
CRL4Cdt2 may allow the onset of CDK activity necessary for this to occur.  In this regard, our 
observation of the relatively delayed timing of p21 destruction at the G1/S transition may 
also have implications for controlling the timing of Cdk2-mediated phosphorylation of 
substrates required for SCFSkp2 targeting.  Further examination of the timing with which 
these E3 ubiquitin ligases act on their substrates will be interesting to explore in future 
experiments. 
Future Directions for Chapter 3 
 As noted in the Discussion section for Chapter 3, using our large-scale MCM2 
92                                                                                                                                     
immunoprecipitation and LC-MS/MS approach, we were able to uncover some previously 
uncharacterized MCM interactions.  Further follow-up analyses is warranted to determine 
their roles in controlling origin licensing/DNA replication.  For instance, our next step after 
validation of interactions by co-IP and western blotting (which we have already 
accomplished for some proteins on our list) will be to perform further functional analyses to 
manipulate the expression/activity of candidate proteins.  We will perform siRNA 
knockdowns and over-express candidate MCM interactors and determine cellular 
consequences for MCM loading during G0/G1 as well as cell cycle progression (measured 
by flow cytometry analysis of DNA content).  We will also assess expression levels and 
subcellular localization of candidate interactions in a variety of cell types to further define 
their involvement in controlling origin licensing and replication onset.  Hopefully, based on 
these analyses, we will be able to better define the roles of these proteins in establishing 
and maintaining unlicensed chromatin during quiescence. 
 Future directions for this project will also prioritize improving our original screening 
approach.  Our original experiment had some obvious limitations, including the fact that our 
list of G0- and G1-induced MCM interactions was relatively short and inconclusive.  As 
mentioned in the Discussion of Chapter 3, we are currently developing an alternative 
screening strategy which exploits the promiscuous biotin ligase BirA*.  We hope that 
proteins purified using this proximity-dependent labeling approach represent more probable 
MCM interactions and that this technique allows for identification of weaker affinity/ 
transiently-associated proteins.  If we still do not uncover many proteins that differentially 
bind G0 and G1 MCM complexes, we may also explore other potential explanations for 
licensing inhibition in G0.  For instance, we could perform phospho-enrichment prior to mass 
spectrometry analysis to identify dynamically regulated phosphorylation sites between 
purified G0 and G1 MCM complexes.  Even if our candidate proteins are not necessarily 
involved in licensing control, we could also investigate their involvement in other aspects of 
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cell cycle regulation.  Ultimately, we hope that any new MCM interactions we uncover from 
these screens will increase our understanding of MCM loading regulation during the cell 
cycle. 
 Success with these screens will greatly facilitate studies of quiescence control in 
several ways.  The identification of new MCM loading inhibitors in quiescent cells may 
provide new biomarkers to further distinguish quiescent vs. proliferating cells in culture.  
Also, increased understanding of their function in maintaining quiescence may allow us to 
make more accurate predictions on how to manipulate cell proliferation pharmacologically.  
A defining feature of several types of cancer cells is their inability to establish and maintain 
cellular quiescence.  Identification of hits from our screen which are also differentially 
regulated in cancer cells will be quite impactful, as such information may potentially guide 
therapeutic efforts to selectively target cancer vs. normal cells. 
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APPENDIX: CDK1-DEPENDENT INHIBITION OF THE E3 UBIQUITIN LIGASE, CRL4CDT2, 
ENSURES ROBUST TRANSITION FROM S PHASE TO MITOSIS3 
Project Summary 
 In addition to my main dissertation work detailed in Chapters 2 and 3, I also made 
substantial contributions to another publication investigating the inhibition of CRL4Cdt2 
targeting during the S/G2 transition.  In this paper, on which former graduate student 
Lindsay Rizzardi is first-author, we discovered that the CRL4Cdt2 substrates p21, Cdt1, and 
PR-Set7 re-accumulate beginning in late S phase, in spite of the persistence of PCNADNA.  
Furthermore, these substrates are protected from UV-triggered CRL4Cdt2 targeting during 
mitosis.  We demonstrated that a CDK1-dependent mechanism blocks CRL4CDT2 activity 
during the S/G2 transition by interfering with CDT2 recruitment to chromatin.  Based on this 
evidence, we conclude that the CDK1-dependent override of replication-coupled destruction 
in late S phase contributes to substrate re-accumulation at this point in the cell cycle, 
allowing for the efficient transition from S phase to mitosis. 
 My specific contributions to this paper are listed below.  Portions of text from the 
manuscript highlighting these findings are indicated by [ ]. 
 Contributions to Rizzardi et al., 2014 
(1)  The UV-triggered degradation of CRL4Cdt2 substrates Cdt1, p21 and PR-Set7 
                                                 
3 Modified from Rizzardi, L.F., D. Varma, K.E.Coleman, J.P. Matson, S. Oh, J.G. Cook. (2014) 
CDK1-dependent  Inhibition of the E3 Ubiquitin Ligase, CRL4CDT2, Ensures Robust Transition from S 
Phase to Mitosis. J. Biol. Chem. 290: 556-567. 
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is blocked in nocodozole-arrested cells (Figure A.2A and B). 
(2) CDK-1 inhibition with the drug RO-3306 was shown to block the re-
accumulation of substrates during the late S phase/G2 transition.  I provided 
flow cytometry analysis to show that synchronized cells treated with RO-3306 
experienced a G2 arrest as expected, but were still allowed to progress 
normally through late S phase (Figure A.4A and B). 
(3) Similarly to WT-p21, a p21 construct harboring alanine substitutions at two 
phosphorylation sites previously reported to stabilize p21, T57 and S130 (HA-
p21-AA), was still resistant to CRL4Cdt2-mediated proteolysis in mitosis.  This 
result further suggests that CRL4Cdt2 is itself inhibited during this transition, 
and that direct substrate phosphorylation is not required for protection from 
CRL4Cdt2-mediated destruction in mitosis (Figure A.5A). 
(4) While PCNA is still recruited to chromatin in nocodozole-arrested cells, Cdt2 
is not.  This inhibition of Cdt2 chromatin association prevents recognition of 
CRL4Cdt2 substrates in mitosis, leading to their stabilization (Figure A.6A). 
(5) Cdt2 chromatin binding is lost as CDK1 activity rises in late S phase, 
coinciding with the timing of substrate re-accumulation (with Jacob Matson) 
(Figure A.6C). 
Introduction 
Ubiquitin-mediated degradation of cell cycle proteins is essential to ensure timely cell 
cycle transitions that maintain genome integrity. Conversely, cell cycle-dependent protein 
stabilization by preventing ubiquitination allows rapid protein accumulation at the right time 
to bring about robust cell cycle transitions. Replication-coupled destruction is a particularly 
important protein control mechanism that coordinates the degradation of a cohort of proteins 
with the process of DNA synthesis. Much has been learned about how replication-coupled 
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destruction is initiated in S phase (Arias and Walter 2005; Kim et al. 2008; Tardat et al. 
2010; Terai et al. 2013; Zhang et al. 2013), but less is known about how it is inhibited as S 
phase ends. 
Among the cohort of human proteins reported to be subject to replication-coupled 
destruction are CDT1, SET8, p12, the CDK inhibitor p21, and most recently, thymine DNA 
glycosylase (TDG) (Shibata et al. 2014; Slenn et al. 2014). Their destruction in S phase is 
particularly critical to ensure precise and efficient genome duplication (Arias and Walter 
2005; Kim et al. 2008; Tardat et al. 2010; Terai et al. 2013; Zhang et al. 2013; Shibata et al. 
2014; Slenn et al. 2014). CDT1 is required in G1 for rendering DNA replication origins 
competent for initiation in S phase (a process termed origin licensing) (Nishitani et al. 2000; 
Maiorano et al. 2000). SET8 is the sole enzyme responsible for histone H4 lysine 20 
monomethylation (H4K20me1) and, like CDT1, is also required for origin licensing (Tardat et 
al. 2010). Degradation of CDT1 and SET8 at the onset of S phase restricts DNA replication 
to no more than once per cell cycle by preventing re-licensing of replicated origins. Failure to 
degrade either CDT1 or SET8 results in multiple rounds of origin firing leading to DNA re-
replication and ultimately significant DNA damage and genome instability (Arias and Walter 
2005; Tardat et al. 2010; Abbas et al. 2010; Arias and Walter 2006; Kerns et al. 2007; Li and 
Blow 2005; Takeda et al. 2005; Vaziri et al. 2003; Yoshida et al. 2005). Likewise, 
persistence of human thymine DNA glycosylase in S phase slows proliferation (Shibata et 
al. 2014). Degradation of p21 in early S phase stimulates CDK2 activity which in turn, 
triggers key S phase events including DNA replication initiation and origin licensing inhibition 
(Abbas et al. 2008; Nishitani et al. 2008). During S phase, p12 levels are 35% of their G2/M 
and G1 levels resulting in the presence of both Polδ3 (Polδ lacking p12) and Polδ4 (Polδ 
containing p12) during S phase (Zhang et al. 2013). Since the two forms of Polδ have 
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complementary biochemical properties (Zhang et al. 2013; Meng et al. 2010), CRL4CDT2-
mediated degradation of p12 during S phase may be important for DNA replication fidelity.  
Each of the proteins known to be subject to replication-coupled destruction follows a 
pattern of low abundance during S phase then rapid re-accumulation prior to mitosis 
(illustrated in Figure A.1). Importantly, CDT1, p21, and SET8 also function during mitosis, 
making their re-accumulation critical for normal mitotic progression (Varma et al. 2012; Kreis 
et al. 2013; Wu et al. 2010). Replication-coupled destruction is triggered by the ubiquitin E3 
ligase, CRL4CDT2. The mechanism of CRL4CDT2 substrate recognition is unique in that the 
substrates must first interact with DNA-loaded PCNA (PCNADNA), and PCNA is DNA-loaded 
during both S phase and DNA repair (Arias and Walter 2007; Higa et al. 2003; Machida et 
al. 2005; Teer et al. 2006). Given the robust re-accumulation of CRL4CDT2 substrates well in 
advance of mitosis, we sought to determine the relationship between PCNA unloading in 
late S phase and re-accumulation of CRL4CDT2 substrates. 
We have discovered that surprisingly, CRL4CDT2 substrates accumulate prior to 
PCNA unloading and the completion of replication. Moreover, we demonstrate that 
activation of CDK1 inhibits degradation of CRL4CDT2 substrates. We show here that CDK1 
activity (either directly and/or indirectly) inhibits CRL4CDT2 activity itself by preventing its 
accumulation on chromatin, an event necessary for CRL4CDT2 activity. Activation of CDK1 as 
S phase completes is necessary for the normal re-accumulation of substrates such as CDT1 
and SET8, and we show that, like CDT1, failure to re-accumulate SET8 de novo prior to 
mitosis leads to mitotic progression defects (Varma et al. 2012). The temporal control of 
CRL4CDT2 activity ensures the accumulation of CRL4CDT2 substrates during mitosis, thereby 
preventing chromosome instability. We propose that purposeful protection from replication-
coupled destruction anticipates the end of S phase and primes efficient progression through 
mitosis.  
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Results 
CRL4CDT2 substrate accumulation occurs in late S phase prior to PCNA unloading.   
 Previous work described replication-coupled destruction of CRL4CDT2 substrates and 
further documented their robust accumulation at later cell cycle stages illustrated in Figure 
1A. Given that PCNA loading at replication and repair sites (“PCNADNA”) is a prerequisite for 
CRL4CDT2 targeting, the normal substrate re-accumulation as S phase ends could simply be 
a consequence of PCNA unloading as replication completes. Nevertheless, replication can 
extend close to the time of mitosis, and this late replication has been implicated in the 
genome instability associated with common fragile sites (Debatisse et al. 2012). Since 
PCNADNA triggers CRL4CDT2- mediated degradation, persistence of PCNADNA so late in S 
phase was not fully consistent with observations by us and others that CRL4CDT2 substrates 
re-accumulate well in advance of mitosis (Zhang et al. 2013; Abbas et al. 2010; Nishitani et 
al. 2008; Chandrasekaran et al. 2011). We therefore considered the possibility that 
substrates may be actively stabilized during the transition from S phase to mitosis. If so, 
then CRL4CDT2 substrates may in fact accumulate prior to PCNADNA unloading.  
To test this idea we interrogated the timing of CRL4CDT2 substrate accumulation in 
individual cells relative to the dynamics of PCNADNA unloading as cells completed S phase. 
We synchronized cells in early S phase, released them to proceed to late S phase, and then 
extracted soluble proteins prior to fixation and immunostaining for endogenous PCNADNA 
and the CRL4CDT2 substrates CDT1, p21, and SET8. As expected, cells in early S phase had 
abundant PCNADNA in a characteristic early S phase pattern (Leonhardt et al. 2000) but had 
very little CDT1 (Figure A.1B, top row) and similarly low levels of p21 and SET8 (Figures 
A.1C and D, top rows). In late S phase (7 hours post release), PCNA was still DNA-loaded 
in some cells, and CDT1, p21, and SET8 were readily detectable in those same cells 
(Figure A.1B, bottom row, A.1C, and D). Late S phase cells are characterized by foci of 
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chromatin-bound PCNA at the nuclear periphery with more diffuse nuclear staining 
elsewhere as seen in Figure A.1B and C (Leonhardt et al. 2000). (Multiple mechanisms 
recruit these proteins to chromatin resulting in only partial co-localization with PCNA foci.) 
We counted the number of cells that retained PCNADNA foci 7 hours into S phase (14%, 
n=150) and then scored those that also contained nuclear p21, SET8, or CDT1 using 
antibodies to the endogenous proteins. We found that 40-65% of PCNADNA-positive cells 
already had abundant CRL4CDT2 substrates (Figure A.1E, we cannot distinguish differences 
among the individual substrate kinetics from differences in antibody avidity). Importantly, 
individual late S phase cells that retained PCNADNA had nearly equivalent amounts of 
PCNADNA relative to their early S phase counterparts (Figure A.1F). Thus, the accumulation 
of substrates was not accounted for by the amount of PCNADNA declining in individual late S 
phase cells. The fact that cells with similar amounts of PCNADNA showed dramatically 
different abilities to support replication-coupled destruction indicates a qualitative difference 
between early and late S phase cells with regard to CRL4CDT2 activity.  Moreover, the 
presence of CDT1, SET8, and p21 in late S phase nuclei with PCNADNA suggested an active 
mechanism to inhibit CRL4CDT2-mediated degradation.  
CRL4CDT2 substrates cannot be targeted during mitosis.   
[It is worth noting that at 7 hours post-release (Figure A.1), not every cell contained 
both PCNADNA and CRL4CDT2 substrates consistent with the observation that even in 
synchronized cells, progression through S phase is not perfectly uniform. Our time courses 
indicate that the onset of CRL4CDT2 substrate accumulation occurs during the final ~10-15% 
of S phase based on an average 7-8 hour S phase and mitotic entry at 8-9 hours (e.g. 
Figure A.4A). Since we could not arrest cells in very late S phase for biochemical analysis, 
we took advantage of the next available robust cell cycle block in prometaphase, which is    
 
100                                                                                                                                     
Figure A.1. 
 
Figure A.1. Targets of replication-coupled destruction re-accumulate prior to the end 
of S phase. A, In early S phase PCNA is loaded onto DNA and is bound by CRL4CDT2 
substrates (e.g. CDT1). The interaction of substrates with PCNADNA recruits the CRL4CDT2 E3 
ubiquitin ligase via the CDT2 substrate receptor subunit for replication-coupled destruction.  
B, HCT116 cells were synchronized in early S phase by double-thymidine block. Soluble 
proteins were extracted, and bound proteins were fixed in early S phase (during the arrest) 
or in late S phase 7 h after release into fresh medium. Endogenous PCNADNA and CDT1 
were detected by immunostaining.  
C and D, as in B except that p21 or SET8 were detected by immunostaining. Scale bars = 5 
µm in B-D.  
E, The percent of late S phase cells containing PCNADNA that also contained SET8 (n = 60), 
p21 (n = 100), or CDT1 (n = 122) was quantified.  
F, Total PCNA nuclear fluorescence was quantified for the early and late S phase samples 
in B (n = 15). A total of 60 cells were counted over three biological replicates (>15 cells were 
counted per replicate). Averages and standard deviations are indicated in both E and F. 
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1-2 hours later, to generate homogenous cell populations. To determine if CRL4CDT2 
substrates are actively protected from degradation late in the cell cycle, we deliberately 
stimulated synchronous replication-coupled destruction by UV-irradiating prometaphase 
cells. UV irradiation causes robust and simultaneous PCNA loading onto DNA during 
nucleotide excision repair, and thus UV treatment causes highly synchronous replication-
coupled destruction of CRL4CDT2 substrates by the same mechanism that operates during S 
phase (reviewed in (Abbas and Dutta 2011)). (Note that CRL4CDT2-mediated degradation is 
stimulated by DNA synthesis per se and is not a component of the DNA damage checkpoint 
response (Higa et al. 2003)). We monitored the levels of CDT1 as well as three other 
CRL4CDT2 substrates by immunoblotting lysates from the two conditions. As expected in 
asynchronous cells, CDT1, SET8, p21, and p12 were degraded following UV irradiation 
(Figure A.2A and A.2B, lanes 1 and 2). In stark contrast however, none of the four 
substrates were degraded in prometaphase cells (Figure A.2A and B, lanes 3 and 4).] 
CRL4CDT2 substrates are resistant to degradation in some quiescent cells because 
the substrate adapter subunit, CDT2, is itself degraded (Abbas et al. 2013b; Rossi et al. 
2013). CDT2 was equally present in both asynchronous and prometaphase cells, so the 
substrate protection we observed could not be attributed to loss of CDT2 under these 
conditions (Figure A.2B, lanes 3 and 4). Importantly, releasing mitotic cells into the 
subsequent G1 fully restored sensitivity of SET8 and CDT1 to CRL4CDT2-mediated 
degradation (Figure A.2C). SET8 is also an APC/C target (Wu et al. 2010), and we 
observed the expected low SET8 levels in untreated G1 cells relative to mitotic cells. Taken 
together, we conclude that the substrates of CRL4CDT2 are protected from degradation in a 
cell cycle-dependent manner. 
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Figure A.2. 
 
Figure A.2. CRL4CDT2 substrates are protected in mitosis.  
[A and B, HCT116 cells were grown asynchronously (“Async.”) or synchronized in 
prometaphase by release from a thymidine block into 100 nM nocodazole for 10 h (“M”). 
Cells were irradiated with 20 J/m2 UV to induce PCNADNA loading (DNA repair synthesis) 
and harvested 2 h later or left untreated as indicated. Endogenous proteins were detected in 
whole cell lysates by immunoblotting (* in A denotes a nonspecific background band).]  
C, HCT116 cells were synchronized in prometaphase as in A and released into fresh media 
for 2.5 h to proceed to G1. Cells were UV irradiated and harvested 90 min later followed by 
immunoblotting for the indicated proteins. 
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Mitotic kinase activity is required for protection from CRL4CDT2-mediated degradation.   
Our observation that CRL4CDT2 substrates are stable from late S phase through 
mitosis but susceptible to replication-coupled destruction during G1 suggested that a mitotic 
activity, such as one or more mitotic protein kinases, confers protection from CRL4CDT2-
mediated degradation. To test that possibility, we employed pharmacological inhibition of 
candidate kinases: cyclin-dependent kinases (CDKs) and the stress-activated mitogen-
activated protein kinases (MAPK) p38 and JNK, which we previously showed could stabilize 
CRL4CDT2 substrates (Chandrasekaran et al. 2011). We briefly treated prometaphase cells 
with kinase inhibitors prior to UV irradiation then tested for reversal of mitotic stability by 
immunoblotting (Figure A.3A and B). In control cells as before, CRL4CDT2 substrates were 
stable in mitotic cells, but strikingly, treatment with the CDK1-specific inhibitor RO-3306 
effectively reversed the protection (Figure A.3A, compare lanes 4 and 6; Figure A.3B, 
compare lanes 4 and 5). In contrast, treatment with the p38 or JNK inhibitors had little-to-no 
effect on substrate protection (Figure A.3B, lanes 6 and 7). Note that both p38 and JNK are 
active not only in mitosis but are also induced by UV (Yujiri et al. 1999; Takenaka et al. 
1998); the JNK and p38 inhibitors were effective for inhibiting their respective kinases at 
these concentrations as measured by phosphorylation of representative substrates (Figure 
A.3B bottom panels). CDK1 inhibition also caused Cyclin B1 degradation (Figure A.3B, 
lanes 5 and 8), which is consistent with prior studies showing that inhibiting CDK1 in mitotic 
cells activates APCCdc20 (Pesin and Orr-Weaver 2008; Yu 2007). (SET8 is also an APCCdc20 
target, but SET8 phosphorylation during mitosis blocks APCCdc20 binding so SET8 was not 
degraded in cells treated with the CDK1 inhibitor alone (Wu et al. 2010)). Importantly, only 
CDK1 inhibition re-sensitized CRL4CDT2 substrates in mitosis (Figure A.3B compare lane 4 
with lanes 5, 6, and 7). Even simultaneous inhibition of p38 and JNK could not substitute for 
CDK1 inhibition (data not shown). Furthermore, increasing concentrations of the CDK1 
inhibitor resulted in progressive loss of CRL4CDT2 substrate protection (Figure A.3C). 
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We confirmed that re-acquisition of UV-induced degradation in CDK1-inhibited cells 
was still CUL4-dependent by co-treatment with the neddylation inhibitor, MLN4924 (Figure 
A.3D, compare lanes 6 and 8). Together, these data indicate that CDK1 activity is required 
for the protection of CRLCDT2 substrates from replication-coupled destruction. 
CDK1 activity is required for substrate CRL4CDT2 re-accumulation in late S phase.   
 [To understand the relationship of CDK1 activity in late S phase cells to the kinetics 
of CRL4CDT2 substrate re-accumulation, we treated synchronized cells in mid-S phase (5 
hours post thymidine release) with the CDK1 inhibitor. We then monitored both cell cycle 
progression and the anticipated re-accumulation of CDT1 and SET8 as S phase completed 
(Figures A.4A and B). Treatment with the CDK1 inhibitor, RO-3306, in asynchronous cells 
results in a G2 arrest (Vassilev 2006), and as expected it blocked cells released from early S 
synchronization, but CDK1 inhibition did not prevent S phase completion (Figure A.4A).  
However, CDK1 inhibition strongly and reproducibly dampened the normal late S and G2 
increase in both SET8 and CDT1 protein levels (Figure A.4B), compare lanes 5-8 to lanes 
10-13). The levels of Cyclin A and Cyclin B1 at the 7 and 8 hour time points corresponding 
to late S and G2 phases were unperturbed by the inhibitor, but at the normal time of mitosis 
(at 9 hours) CDK1 inhibition caused premature Cyclin B1 loss, consistent with results in 
nocodazole-arrested cells (Figure A.3B, lanes 9-11). Importantly, these effects on Cyclin B1 
levels happened 2 hours after the delay in CDT1 and SET8 re-accumulation.] 
We once again examined individual late S phase cells (7 hours post-release) for the 
presence of both PCNADNA and SET8 or CDT1. In a substantial proportion of control 
PCNADNA-positive cells SET8 and CDT1 had already re-accumulated, similar to Figure A.1E 
(Figure A.4C). When CDK1 was inhibited starting at 5 hours post S phase release however, 
the percent of double positive cell decreased nearly two-fold (Figure A.4C). Since the 
effects of CDK1 inhibition on CRL4CDT2 substrate accumulation occurred well in advance of  
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Figure A.3. 
 
Figure A.3. CDK1 activity is required for CRL4CDT2 substrate protection.  
A, Asynchronous or prometaphase HCT116 cells were treated with the CDK1 inhibitor RO-
3306 as indicated 30 min prior to PCNADNA induction by UV and harvested 2 h later.  
B, Top panel: Asynchronous or prometaphase cells were treated with the indicated kinase 
inhibitors or DMSO (“none”) for 30 min prior to PCNADNA induction by UV irradiation. 
Endogenous proteins were detected by immunoblotting of whole cell lysates Bottom panels: 
Asynchronous cells were treated with the inhibitor JNK VIII or SB203580 (p38 inhibitor) 30 
min prior to treatment with 250 mM NaCl and/or UV irradiation as indicated. 
(Hyperphosphorylated c-JUN migrates significantly slower than the partially phosphorylated 
form). 
C, Asynchronous or prometaphase HCT116 cells were treated with indicated concentrations 
of RO-3306 for 30 min prior to UV irradiation and harvested 1 h later.  
D, Asynchronous or prometaphase cells were untreated (-) or treated with UV (+) to induce 
PCNADNA and harvested 1 h after treatment. The CDK1 inhibitor RO-3306 and/or the CUL4 
neddylation inhibitor MLN4924 (5 µM) were added 30 min prior to UV irradiation as 
indicated. 
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mitosis, CDK1 activity inhibits CRL4CDT2 not only in prometaphase-arrested cells, but also 
during the transition from S phase into G2 and mitosis.  
CRL4CDT2 activity is itself inhibited.    
[Our prior work provided evidence for stabilization of CDT1 by direct phosphorylation 
as cells transit from S phase to M phase (Chandrasekaran et al. 2011; Varma et al. 2012). 
Furthermore, our study and that of Kim et. al. (Kim et al. 2002) suggested that a similar 
direct p21 phosphorylation mechanism could control p21 stability. To determine if protection 
from CRL4CDT2-mediated degradation during late cell cycle stages is solely the consequence 
of direct substrate phosphorylation, we expressed epitope-tagged WT p21 (HA-p21-WT) or 
p21 harboring alanine substitutions at the two phosphorylation sites that were reported to 
stabilize p21, T57 and S130 (HA-p21-AA) (Kim et al. 2002). In synchronized cells, both HA-
p21-WT and HA-p21-AA (as well as endogenous p21) migrated slower by SDS-PAGE 
compared to asynchronous cells, and this mobility shift was reversed by phosphatase 
treatment (Figure A.5A, lanes 5 and 10). The HA-p21-AA mutant migrated faster than WT 
HA-p21 in lysates of mitotic cells but was just as stable as both ectopic and endogenous WT 
p21 (Figure A.5A, compare lanes 4 and 8). Residual sites of p21 phosphorylation affect p21 
gel mobility, but have not been shown to affect p21 stability ((Hodeify et al. 2011) and 
reviewed in  and reviewed in (Child and Mann 2006)). Nevertheless, mitotic phosphorylation 
of p21 at T57 and S130 is not the principal reason p21 is stable in mitotic cells.] 
We similarly expressed epitope-tagged versions of WT CDT1 and CDT1 harboring 5 
alanine substitutions (CDT1-5A) at the mitotic phosphorylation sites we had previously 
shown to stabilize CDT1. Specifically, we had shown that CDT1-5A is not protected from  
CRL4CDT2 by stress MAP kinase activation (Chandrasekaran et al. 2011). These cells were 
then subjected to UV irradiation during asynchronous culture or after synchronization in 
prometaphase. Both endogenous CDT1 and epitope-tagged WT CDT1 were protected in  
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Figure A.4. 
 
Figure A.4. CDK1 activity is required for substrate re-accumulation in late S phase. [A, 
HCT116 cells were synchronized in early S phase via double thymidine block and 5 h after 
release were treated with RO-3306 or DMSO (control). Cells were harvested at the indicated 
time points and analyzed for DNA content by flow cytometry.  
B, HCT116 cells were treated as in A harvested at the indicated time points and analyzed 
via immunoblotting.]  
C, HCT116 cells were treated as in A. Soluble proteins were extracted, and bound proteins 
were fixed in early S phase (during the arrest) or in late S phase 7 h after release into fresh 
medium. Endogenous PCNADNA, SET8, and CDT1 were detected by immunostaining as in 
Figure 1. Late S phase cells containing PCNADNA were scored for the presence of SET8 or 
CDT1 as an indicator of inactive CRL4CDT2 (n > 75 for each sample). 
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synchronized cells (Figure A.5B, compare lanes 6 and 8), and as expected, both WT 
proteins migrated slower by SDS-PAGE compared to asynchronous cells. CDT1-5A 
migrated slightly faster than WT CDT1 from lysates of mitotic cells, consistent with our prior 
analysis of this mutant. The clear residual mitotic shift of this mutant is consistent with 
additional phosphorylation sites in CDT1 that may or may not affect its stability (Miotto and 
Struhl 2011; Liu et al. 2004; Sugimoto et al. 2004). Like the p21-AA mutant, CDT1-5A was 
just as stable as both ectopic and endogenous CDT1 in prometaphase cells indicating that 
phosphorylation at these sites previously shown to stabilize CDT1 is not solely responsible 
for CDT1 mitotic stability (Figure A.5B, lanes 9-12). Together, these observations indicate 
that protection from CRL4CDT2 likely involves more than phosphorylation of the substrates 
themselves. Moreover, the fact that all four of the tested CRL4CDT2 substrates were resistant 
to degradation suggests that CRL4CDT2 is globally suppressed during progression from late S 
phase into mitosis. 
To probe the activity of CRL4CDT2 itself in mitosis, we designed two reporter 
constructs for stable expression in which the N-terminal 28 amino acids of CDT1 were fused 
to either red fluorescent protein (RFP) or the SNAP-tag (Keppler et al. 2003). The N-terminal 
28 amino acids contain CDT1’s PIP degron and was previously shown to confer CUL4-
dependent degradation to a heterologous protein (Senga et al. 2006). Importantly, neither 
reporter construct contains canonical CDK or MAPK phosphorylation sites. In 
asynchronously growing cells, the SNAP reporter fusion was degraded following UV 
irradiation (Figure A.5C, lanes 1 and 2); however, in prometaphase cells the reporter was 
stable (Figure A.5C, lanes 3 and 4). Furthermore, CDK1 inhibition re-sensitized the SNAP 
reporter to degradation (Figure A.5C, lanes 5 and 6) indicating that regulation of this 
reporter is similar to endogenous CRL4CDT2 substrates. We observed nearly identical CDK1-
dependent stabilization of the RFP reporter (Figure A.5D). These findings indicate that the 
ability of CRL4CDT2 to target substrates is generally inhibited via a CDK1-dependent event 
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independently of any additional phosphorylation-mediated mechanisms of direct substrate 
stabilization. 
CDK1 activity prevents chromatin association of CDT2.   
[During productive CRL4CDT2 targeting, PCNA is first loaded onto DNA for replication 
(S phase) or repair (e.g. post-UV). Proteins containing PIP degrons bind to PCNADNA, and 
the resulting complex is then recognized by the substrate receptor, CDT2 (Havens and 
Walter 2009). We postulated that one or more of these steps is inhibited by CDK1. We first 
tested if PCNA can be successfully loaded onto mitotic chromatin by UV-irradiating 
nocodazole-synchronized cells then analyzing chromatin fractions. We detected PCNA in 
chromatin fractions from untreated asynchronous cells (reflecting the S phase fraction; 
Figure A.6A, lane 7), and PCNADNA was further induced by UV irradiation, which stimulates 
PCNA loading in all cell cycle phases (Figure A.6A, lane 8). As previously reported, CUL4A 
is also recruited to chromatin following UV irradiation (Groisman et al. 2003; Guerrero-
Santoro et al. 2008; Kapetanaki et al. 2006), and as expected, a resident chromatin protein, 
ORC2,  is unaffected (Figure A.6A). In otherwise untreated mitotic cells, PCNA was not 
DNA-associated (as expected), but was loaded following UV irradiation (Figure A.6A, lane 
10). Thus, mitotic chromatin is not intrinsically resistant to PCNA loading. In addition, PCNA 
from extracts of mitotic and asynchronous cells showed similar binding to recombinant p21 
(but not a p21 PIP box mutant) in vitro (Figure A.6B). In stark contrast to PCNA, CDT2 
could not be inducibly recruited to mitotic chromatin though it was readily recruited to 
chromatin in asynchronously growing cells (Figure A.6A, compare lanes 8 and 10). Finally, 
CDK1 inhibition restored CDT2 chromatin recruitment in mitotic cells (Figure A.6A, compare  
lanes 10 and 12). Thus, the CDK1-dependent inhibition of CRL4CDT2- mediated degradation 
operates by interfering with chromatin recruitment of the CDT2 substrate receptor. 
Consistent with this finding, we noted that CDT2 is lost from chromatin fractions in late S  
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Figure A.5. 
 
 
Figure A.5. CDK1- dependent inhibition of CRL4CDT2 activity. [A, HCT116 cells stably 
expressing HA-tagged WT or p21-AA (T57A and S130A mutations) were grown 
asynchronously or arrested in prometaphase. Cells were harvested 2 h after PCNADNA 
induction by UV irradiation; cell lysates were treated with λ-phosphatase (Ppase) prior to 
SDS-PAGE as indicated.]  
B, HeLa cells stably expressing HA-tagged WT or CDT1-5A (39) were grown 
asynchronously or arrested in prometaphase. Cells were harvested 1 h after PCNADNA 
induction by UV.  
C, HeLa cells stably expressing the illustrated PIP degron-SNAP fusion were grown 
asynchronously or arrested in prometaphase and treated with the CDK1 inhibitor RO-3306 
or control DMSO 30 min prior to PCNADNA induction by UV irradiation; cells were harvested 
1hr after UV.  
D, As in C except with HeLa cells stably expressing a PIP degron-RFP (mCherry) fusion. 
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phase earlier than PCNA itself (Figure A.6C, lanes 11-13) coincident with the normal re-
accumulation time points for CDT1 and SET8 (e.g. Figures A.1B, A.1D and A.4B).] 
De novo SET8 re-accumulation is essential for normal mitotic progression.   
Having demonstrated active inhibition of CRL4CDT2 targeting as cells progress from S 
phase to M phase, we next considered the possible biological significance of this 
mechanism. Replication-coupled destruction via CRL4CDT2 during S phase ensures a single 
round of replication through the destruction of both CDT1 and SET8; their abnormal 
persistence in S phase leads to repeated rounds of origin relicensing and re-replication 
(Arias and Walter 2005; Tardat et al. 2010). On the basis of these facts alone, it should be 
detrimental to actively accumulate proteins like CDT1 and SET8 prior to the subsequent G1. 
However, CDT1 also has an essential function in mitosis that we recently documented 
(Varma et al. 2012), thus providing incentive for high levels of CDT1 before mitosis. In 
addition, sufficient levels of p21 are required in mitosis for normal mitotic progression (Kreis 
et al. 2013). Given that all CRL4CDT2 substrates follow a similar pattern of mitotic 
stabilization, we postulated that CDT1 is not the only substrate needed in abundance and de 
novo at the end of S phase, and we turned our attention to SET8. Depleting SET8 from 
asynchronous cells leads to multiple defects including not only inefficient origin licensing in 
G1 but also impaired chromatin condensation in mitosis. Thus far, these phenotypes have 
all been attributed to the loss of SET8-deposited histone H4K20me1 (Tardat et al. 2010; Wu 
et al. 2010; Oda et al. 2010). However, it is not yet known if the mitotic defects from SET8 
depletion are due to the absence of SET8 specifically during G2 and mitosis or if they arise 
secondarily from the absence of SET8 in a prior cell cycle phase such as G1. It is possible  
that SET8 activity deposits the essential methylations for chromosome condensation during 
G1 making SET8 dispensable during G2. 
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Figure A.6. 
 
Figure A.6. CDK1 activity prevents CDT2 chromatin recruitment. [A, HCT116 cells were 
grown asynchronously or synchronized in prometaphase. Cells were treated with DMSO 
(“none”) or the CDK1 inhibitor RO-3306 for 30 min prior to PCNADNA induction by UV 
irradiation and harvested 90 min later. Endogenous proteins in whole cell extracts and 
chromatin-bound fractions were analyzed by immunoblotting.]  
B, GST, GST-p21WT, or GST-p21PIP were produced in E. coli and bound to glutathione 
beads. The protein-coated beads were then incubated with whole cell lysates from 
asynchronous or mitotic cells as described in (39). Endogenous PCNA and GST-tagged p21 
were detected by immunoblotting.  
[C, HCT116 cells were synchronized in early S phase via double thymidine block and 
released into fresh media. Cells were harvested at the indicated time points. Endogenous 
proteins in whole cell extracts and chromatin-bound fractions were analyzed by 
immunoblotting.] 
 
113                                                                                                                                     
 
To determine if SET8 is required specifically during transit from late S phase into 
mitosis, we employed a synchronization-knockdown procedure we developed during the 
investigation of CDT1’s mitotic function. We synchronized cells in early S phase after the G1 
function of SET8 had been fully completed and released them in the presence of either 
control or SET8 siRNA to proceed otherwise unperturbed through S phase (Figure A.7A). 
SET8 siRNA effectively prevented accumulation of both SET8 and monomethylation of 
histone H4K20 after S phase (Figure A.7B, compare lanes 2-7 to lanes 8-13). Of note, 
SET8 depletion also caused a reduction in H4K20me2 indicating that establishment of 
histone H4K20me1 during late S phase is required to maintain H4K20me2 levels during G2 
and mitosis. H4K20me1 has recently been shown to be required for proper kinetochore 
assembly (Hori et al. 2014). Our data clearly support this finding and further indicate that this 
deposition occurs during G2/M as SET8 re-accumulates (Figure A.7B).  
We examined mitotic chromosome morphology in the synchronized SET8-depleted 
cells by staining for DNA with DAPI and for the mitotic spindle with anti-tubulin. Control cells 
analyzed 10 hours after release from the early S phase block contained metaphase 
chromosomes that were fully condensed and properly aligned at the metaphase plate 
(Figure A.7C, top panel). In contrast, chromosomes in cells that had normal SET8 in G1, 
but contained little-to-no SET8 only in G2 were less dense and formed a “cloud” of DNA that 
failed to align properly in metaphase (Figure A.7C, bottom panels). We replicated both the 
failure to re-accumulate normal H4K20me1 and the mitotic chromosome condensation 
defects using a different SET8 siRNA in synchronized cells (Figure A.7D). Furthermore, we 
quantified mitotic progression 10 hours after thymidine release: cells with normal SET8 in 
G1 but blocked from re-accumulating SET8 in late S/ G2 were significantly enriched in pre-
anaphase states with a corresponding decrease in cells that had completed anaphase at 10  
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Figure A.7. 
 
 
Figure A.7. De novo SET8 re-accumulation after S phase is necessary for normal 
mitotic progression. A, Illustration of the experimental approach to block SET8 re-
accumulation only after S phase.  
B, HCT116 cells were synchronized in early S phase via double-thymidine block. Cells were 
released into fresh medium containing control (luciferase) or SET8-ORF siRNA and 
harvested at the indicated time points for immunoblotting of the indicated endogenous 
proteins (* denotes a nonspecific background band).  
C, Cells were synchronized as in A then released into siRNA-containing medium for 10 h 
prior to fixation and immunofluorescence staining for tubulin and DAPI staining for DNA. 
Scale bar = 5 µm.  
D, The number of mitotic cells from C in pre-anaphase vs. anaphase/telophase was 
quantified in three biological replicates (n=300 for each replicate) using two different siRNAs 
as indicated. 
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hours (Figure A.7D). These data highlight the importance of SET8 re-accumulation, and by 
extension general CRL4CDT2 inhibition, prior to mitosis for proper chromosome condensation 
and mitotic progression. Thus, CDK1 activity in late S phase and G2 phase is required for 
the normally robust rebound in the levels of CRL4CDT2 substrates, and the re-accumulation 
(of CDT1 and SET8) is important for proper mitotic progression. 
Discussion 
At least three substrates (CDT1, p21, and SET8) have known roles in mitosis (Varma 
et al. 2012; Kreis et al. 2013; Wu et al. 2010; Centore et al. 2010), and it is possible that 
other CRL4CDT2 substrates also have mitotic roles making general substrate stabilization 
important for mitosis. Independent of these mitotic roles, the known substrates of replication-
coupled destruction via CRL4CDT2 are proteins with clear roles in G1 or S phase. For 
example, the early step of origin licensing, minichromosome maintenance complex (MCM) 
recruitment to chromatin, begins in telophase (Nishitani and Lygerou 2002; Dimitrova et al. 
2002). Thus, with respect to origin licensing, once the nuclear envelope reforms in telophase 
the daughter nuclei are G1-like nuclei in a shared cytoplasm. Since telophase occurs just 2-
3 hours after the end of S phase in cultured somatic cells, active inhibition of replication-
coupled destruction may also facilitate G1 events, a notion that has been suggested 
regarding CDT1 accumulation (Ballabeni et al. 2004, 2013; Tsunematsu et al. 2013). Based 
on our findings, this need for early accumulation may apply to the entire cohort of CRL4CDT2 
substrates. 
PCNADNA is an efficient and potent trigger for replication-coupled destruction. The 
bulk of CDT1 can be degraded within minutes of UV irradiation (Chandrasekaran et al. 
2011) and occurs nearly simultaneously with S phase onset (Arias and Walter 2005, 2006; 
Nishitani et al. 2006). The potency of PCNADNA then presents a challenge near the end of S 
phase because CRL4CDT2 substrates are needed in abundance for mitosis and the 
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subsequent G1. (Though CDT1 can also be targeted by CRL1SKP2 (Liu et al. 2004; Senga et 
al. 2006; Nishitani et al. 2006), we have noted in multiple cell lines that CRL4CDT2 is the 
major regulator of CDT1 degradation in S phase (Chandrasekaran et al. 2011).) Replication 
of at least 1% of the genome occurs as late as 90 min prior to the onset of mitosis (Widrow 
et al. 1998), and this late replication requires the continued presence of PCNADNA. Instead of 
a long G2 phase following complete PCNADNA unloading to allow buildup of essential mitotic 
proteins – including those that are actively degraded at the onset of S phase – G2 can be 
short because that buildup begins during late S phase. We detected significant amounts of 
CRL4CDT2 substrates in the same cells that still contained nearly as much PCNADNA as they 
did at the start of S phase. Our findings indicate that CDK1 itself or a CDK1-dependent 
activity overrides the ability of PCNADNA to stimulate CRL4CDT2 recruitment for replication-
coupled destruction. The first active CDK1 complex that appears contains Cyclin A, and this 
form of CDK1 may be responsible for initiating CRL4CDT2 inhibition; later inhibition would be 
accomplished via Cyclin B/CDK1. In keeping with this idea, pharmacological CDK1 inhibition 
blunted CRL4CDT2 substrate re-accumulation at time points that coincide with the expected 
time of Cyclin A/CDK1 activity (Figure A.4B). Interestingly, depleting Cyclin A in early S 
phase-arrested embryonic stem cells prevented accumulation of CDT1 8 hours after release 
(Ballabeni et al. 2011).  
It is clear that the ultimate target(s) of CDK1 (either direct or indirect) is neither 
PCNADNA nor PCNADNA-substrate interactions, but rather the subsequent chromatin 
recruitment of CDT2 (illustrated in Figure A.8). This inhibition is distinct from the recently 
reported SCF-dependent CDT2 degradation and underscores the importance of regulating 
the CDT2 substrate receptor for cell cycle control (Abbas et al. 2013b; Rossi et al. 2013). In 
fact, phosphorylation of CDT2 during S phase promotes interaction with 14-3-3 proteins that 
protect CDT2 from this SCF-mediated degradation (Dar et al. 2014). We and others have  
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Figure A.8. 
 
Figure A.8. Model. CRL4CDT2 substrates are efficiently degraded in early S phase as a 
result of PCNA loading onto DNA (PCNADNA). Beginning in late S phase, active CDK1 
blocks substrate-mediated chromatin recruitment of the CDT2 receptor allowing re-
accumulation of the cohort of CRL4CDT2 substrates that were subject to replication-coupled 
destruction. Many of these substrates are required for normal mitotic progression. 
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noted extensive mitotic phosphorylation of CDT2 in mitotic cells, and human CDT2 bears 19 
conserved ser/thr-pro sites, but it is currently unknown if phosphorylation at these sites 
affects CDT2 substrate interactions. We have found however, that CDT2 binding to CRL4 is 
unaffected in mitosis (data not shown).  Given the number of potential mitotic proline-
directed kinases, the number of potential CDT2 phosphorylation sites, and observations that 
other members of the CRL4CDT2 complex (CUL4A/B and Roc1) are phosphorylated in 
mitosis (Olsen et al. 2010; Dephoure et al. 2008), further studies are required to define the 
mechanism of CRL4CDT2 inhibition. Since the details of how CDT2 contacts the substrate-
PCNADNA remain unknown, we cannot yet explain how a CDK1-dependent event blocks this 
interaction. Importantly however, CDT2 chromatin recruitment could conceivably be 
achieved by any PIP degron-PCNA complex in sufficient abundance, we infer that not only 
is the interaction between CDT2 and the substrates tested here inhibited, but the interaction 
between CDT2 and any as-yet undiscovered substrates is also inhibited. For example, two 
recent reports identified, thymine DNA glycosylase (TDG) as a target of CRL4CDT2 in 
Xenopus and human cells (Shibata et al. 2014; Slenn et al. 2014). The behavior of our two 
reporter substrates and accumulated findings herein suggest that TDG is also protected via 
CDK1.  
Substrates of replication-coupled destruction accumulate beginning in late S phase 
and are abundant in mitosis. In contrast, experimental manipulations that stabilize the 
substrates CDT1 or SET8 throughout S phase cause severe genome damage from origin 
re-licensing and re-firing (Arias and Walter 2005; Tardat et al. 2010; Abbas et al. 2010; Arias 
and Walter 2006; Li and Blow 2005; Jin et al. 2006; Dorn et al. 2009). If the continued 
presence of either CDT1 or SET8 during S phase is toxic, how then do G2 cells tolerate the 
high levels of both CDT1 and SET8 prior to mitosis? In other words, why do the high levels 
of CDT1 and SET8 not trigger re-replication in late S/G2/M? Replication-coupled destruction 
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is only one of many mechanisms that prevent re-replication, but interestingly many of the 
other mechanisms are not fully in place until late in S phase. For example, the CDT1 
inhibitor, geminin, is induced in S phase but its levels are substantially lower in early S 
phase than in late S phase (Wohlschlegel et al. 2000; McGarry and Kirschner 1998). Other 
mechanisms such as the degradation of the largest subunit of the origin recognition 
complex, Orc1, and the nuclear export of the CDC6 licensing protein are also most evident 
in mid-to-late S phase (reviewed in (Arias and Walter 2007)). Further, Cyclin A/CDK2 (mid-
to-late S phase) is a better inhibitor of origin licensing than Cyclin E/CDK2 (early-to mid S 
phase) (Wheeler et al. 2008). In addition, we recently provided evidence that the mitotic 
phosphorylation of CDT1 not only stabilizes CDT1 but also inhibits its licensing activity 
(Chandrasekaran et al. 2011). Of note, these additional mechanisms impacting CRL4CDT2 
substrate targeting likely fine-tune the kinetics of individual substrate degradation and re-
accumulation. Therefore, in early S phase while both geminin and Cyclin A are low, we 
postulate that replication-coupled destruction of CDT1 and SET8 is most critical, but by late 
S phase, it is “safe” for CDT1 and SET8 to accumulate to high levels because the many 
other mechanisms that block origin re-licensing are by then fully established.  
The anticipatory accumulation of proteins and activities prior to the cell cycle phase 
in which they are needed is well established. For example, a series of mid-G1 events 
including CDC6 accumulation results in replication origin licensing during late G1 that is in 
turn essential for S phase execution (Mailand and Diffley 2005). Likewise, Cyclin B1 
accumulation in G2 occurs in advance of M phase. Moreover, the concept of a checkpoint 
that prevents a cell cycle transition until the preceding one is complete is also well known. 
We have explored here a variation on these themes in which an essential regulatory 
mechanism (replication-coupled destruction) is actively inhibited immediately before and 
during the next cell cycle phase (prior to and during M phase). In contrast to a checkpoint 
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that blocks the transition to the next phase, this mechanism blocks regulation of the current 
phase so the next phase can be launched efficiently. Re-accumulation of CRL4CDT2 targets 
to their maximal levels in anticipation of their requirement primes cells for subsequent cell 
cycle events. As such, our discovery of CDK1-mediated inhibition of CRL4CDT2 adds a new 
dimension to a general cell cycle theme: proactive preparation for cell cycle phase launch. 
Materials and Methods 
Cell culture and manipulations  
HCT116, 293T, and HeLa cells were cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Difco) supplemented with 10% fetal calf serum (Sigma). HCT116 and HeLa cells 
were synchronized in early S phase by double thymidine block (2 mM thymidine for 17 
hours, release into fresh media for 9 hours, 2 mM thymidine 15 hours) or in prometaphase 
by treatment with 2 mM thymidine for 18 hours followed by release into 100 nM nocodazole 
for 10 hours as previously described (Whitfield et al. 2002; Grant et al. 2013). Kinase 
inhibitors were used at the following concentrations: c-Jun N-terminal kinase (JNK) inhibitor 
VIII at 10 μM (EMD Millipore), p38 inhibitor SB203580 at 30 μM (LC Laboratories), and the 
CDK1 inhibitor RO-3306 (Sigma) at 10 μM or as indicated. DNA damage was induced by a 
single treatment of 20 J/m2 UV. Small interfering RNA (siRNA) transfections were performed 
with 400 nM of each siRNA duplex using Dharmafect 1 reagent (Dharmacon) according to 
the manufacturer’s guidelines. This high concentration of siRNA was required for efficient 
knockdown given the brief siRNA treatment time. Synthetic duplexed RNA oligonucleotides 
were synthesized by Life Technologies; Luciferase (5’- CUUACGCUGAGUACUUCGA-3’); 
SET8-ORF (5’-GATGCAACTAGAGAGACA-3’) (Tardat et al. 2010); SET8-UTR (5’-
AAGCAUACAAGCCGAACGUU-3’) (Pesavento et al. 2008).  
121                                                                                                                                     
Antibodies  
 Antibodies were purchased from the following sources:  MAPKAP kinase 2, 
phospho-MAPKAP kinase 2 (p-MK2), phospho-cJUN (Ser63), and SET8 from Cell Signaling 
Technologies; hemagglutinin (HA) from Roche; alpha tubulin (DM1A) from Sigma; PCNA 
(PC-10), p21, Cyclin A, Cyclin B1, and Orc2 from Santa Cruz; H4K20me1 from EMD 
Millipore (cat.#04-735); H4K20me2 from Active Motif (cat.#39174); CDT2 and p12 
antibodies were a gift from A. Dutta. Cul4B and Cul4A antibodies were a gift from Y. Xiong. 
Antibodies to human CDT1 have been previously described (Cook et al. 2004). AlexaFluor 
488 and Rhodamine Red-X-labeled donkey secondary antibodies for immunofluorescence 
microscopy were obtained from Jackson ImmunoResearch Laboratories. 
Plasmids and protein lysate preparation  
HA-tagged mutant CDT1 and p21 were generated via PCR and cloned into pLX302 
(Addgene plasmid 25896) (Yang et al. 2011) or pBABE (Addgene plasmid 51070) (Greulich 
et al. 2012) expression vectors, respectively, as were the tagged wild type constructs. 
Plasmids expressing glutathione-S-transferase (GST)-p21WT and GST-p21PIP fusions were 
generated by recombinational cloning between pENTR-p21 derivatives and pDEST15 for N-
terminal GST fusion (Gateway LR clonase; Life Technologies) and expressed in BL21 cells. 
The PIP box was inactivated by site-directed mutagenesis to generate the p21PIP mutant 
(MTDFY to AAAA). Whole-cell lysates were prepared either by direct lysis of equal cell 
numbers in 2X Laemmli sample buffer with 10% β-mercaptoethanol or in CSK buffer 
(supplemented with 0.1% TritonX-100 and protease and phosphatase inhibitors) (Todorov et 
al. 1995). Chromatin-enriched fractions were isolated as previously described (Cook et al. 
2002) by the addition of micrococcal nuclease and CaCl2 to Triton-insoluble pellets to 
release DNA-bound material into the soluble pool and clarified by centrifugation. 
Alternatively, sonication was used to solubilize the chromatin-bound proteins.  
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Protein-protein interaction assays  
Recombinant GST fusion proteins GST-p21WT or GST-p21PIP (mutated PIP box) 
were immobilized on glutathione-Sepharose 4B beads (GE Healthcare). Whole cell extracts 
(from HCT116 cells) were prepared in CSK buffer (supplemented with 0.1% Triton X-100 
and protease and phosphatase inhibitors) and 1 mg of cell lysate was incubated with the 
bound GST-p21 derivatives for 3 hours at 4C. The bound complexes were washed three 
times in complete CSK buffer, resuspended in 50 L of 2X SDS sample buffer, and boiled 
for 5 minutes to elute bound proteins. 
Immunofluorescence microscopy  
 Cells were rinsed briefly in 1X phosphate-buffered saline (PBS, pH 7.4) prior to 
fixation. Cells were typically pre-fixed with 4% paraformaldehyde for 60 seconds, 
permeabilized with 0.5% Triton X-100 for 5 minutes and then fixed for 15 minutes using 4% 
paraformaldehyde. For all immunostaining procedures involving PCNA, the cells were first 
pre-fixed in 2% paraformaldehyde for 60 seconds, then permeabilized with 0.5% Triton X-
100 for 5 minutes and then fixed with 2% paraformaldehyde for 15 minutes followed by -
20°C methanol for 4 minutes. Blocking steps, antibody incubations, and washes were all 
performed in 1X PBS buffer plus 0.1% BSA. All antibody incubations were for 1 hour at 37ºC 
and washes were for 10 minutes at room temperature. DAPI staining (0.1 µg/ml) was 
performed for 10 minutes, and cells were mounted using either Prolong Antifade (Life 
Technologies/Molecular Probes) or VECTASHIELD mounting media (Vector Laboratories, 
Inc.). 
For indirect immunofluorescence microscopy of interphase nuclei, images were 
acquired using Metamorph Software and a 60X/1.4NA (PlanApo) DIC oil immersion 
objective (Nikon) mounted on a Nikon TE300 inverted microscope equipped with a 
Yokogawa CSU10 spinning disk and a Hamamatsu Orca ER cooled CCD camera. For 
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fluorescence intensity measurements, the average values for integrated nuclear PCNA 
fluorescence from control and experimental cell samples were subjected to background 
subtraction to obtain the specific nuclear fluorescence levels. For indirect 
immunofluorescence microscopy of mitotic cells, images were acquired using Metamorph 
Software and a 100X/1.4NA (PlanApo) DIC oil immersion objective mounted on a Leica 
DMIRB inverted microscope equipped with a Photometric HQ2 cooled CCD camera. Scale 
bars = 5 µm in all figures. 
Flow cytometry  
Prior to flow cytometry analysis, cells were trypsinized, fixed in 70% ethanol, and 
treated with propidium iodide/RNase solution according to standard methods. Flow 
cytometry analysis was performed using a Cyan FACScan (DakoCytomation) and Summit 
v4.3 software (DakoCytomation) as described previously (Hall et al. 2008). 
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